<SEC-DOCUMENT>0001104659-22-121217.txt : 20221122
<SEC-HEADER>0001104659-22-121217.hdr.sgml : 20221122
<ACCEPTANCE-DATETIME>20221122160747
ACCESSION NUMBER:		0001104659-22-121217
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20221121
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221122
DATE AS OF CHANGE:		20221122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Surgery Partners, Inc.
		CENTRAL INDEX KEY:			0001638833
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
		IRS NUMBER:				473620923
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37576
		FILM NUMBER:		221410366

	BUSINESS ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
		BUSINESS PHONE:		615-234-5900

	MAIL ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2230583d4_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sgry="http://surgerypartners.com/20221121">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_sgry_surgerypartners.com_20221121 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20221121_20221121 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001638833 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:EntityCentralIndexKey">0001638833</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="sgry-20221121.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-11-21to2022-11-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-21</xbrli:startDate>
        <xbrli:endDate>2022-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECURITIES AND
EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>WASHINGTON, D.C.
20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span>&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>FORM <span id="xdx_900_edei--DocumentType_c20221121__20221121_ze4FpQDNUmFj"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Pursuant to Section
13 or 15(d) of the </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Securities Exchange
Act of 1934</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date
of Report (Date of earliest event reported): <span id="xdx_90A_edei--DocumentPeriodEndDate_c20221121__20221121_zUAL4VJYqfL"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 21, 2022</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_902_edei--EntityRegistrantName_c20221121__20221121_z9SJRfPCqJj9"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:EntityRegistrantName">Surgery Partners, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">(Exact Name of Registrant as Specified in Charter)</span></p>


<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: center; font-size: 10pt; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20221121__20221121_zOQHei2wS7Ul"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
<td style="text-align: center; font-size: 10pt; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityFileNumber_c20221121__20221121_zGjFtAhMBkai"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:EntityFileNumber">001-37576</ix:nonNumeric></span></b></span></td>
<td style="text-align: center; font-size: 10pt; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20221121__20221121_z2sMcKsQsS2i"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:EntityTaxIdentificationNumber">47-3620923</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">(State or Other Jurisdiction <br /> of Incorporation)</td>
<td style="text-align: center; vertical-align: top">(Commission <br /> File Number)</td>
<td style="text-align: center">(IRS Employer <br /> Identification No.)</td></tr>
</table>


<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20221121__20221121_zcebW0e2xZHe"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:EntityAddressAddressLine1">310 Seven Springs Way</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20221121__20221121_zJcV8Q8Tia0j"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:EntityAddressAddressLine2">Suite 500</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="xdx_900_edei--EntityAddressCityOrTown_c20221121__20221121_zjvzUsOKYYn2"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:EntityAddressCityOrTown">Brentwood</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20221121__20221121_zrbtFbs7nFz9"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Tennessee</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20221121__20221121_z9qY2MskjLT5"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:EntityAddressPostalZipCode">37027</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">(Address of Principal Executive Offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<span id="xdx_906_edei--CityAreaCode_c20221121__20221121_z4m3pdXfom2d"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:CityAreaCode">615</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20221121__20221121_zpIx4PFG40yc"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:LocalPhoneNumber">234-5900</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">(Registrant's Telephone Number, Including Area Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Not Applicable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">(Former Name or Former Address, If Changed Since Last Report)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--WrittenCommunications_c20221121__20221121_zV2LEhBMUNS9"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p>

<p style="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Wingdings"><span id="xdx_90B_edei--SolicitingMaterial_c20221121__20221121_zDkY7TF9tho3"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p>

<p style="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Wingdings"><span id="xdx_902_edei--PreCommencementTenderOffer_c20221121__20221121_zB6Plj4PyNO3"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p>

<p style="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementIssuerTenderOffer_c20221121__20221121_zVvhSWk6U7rj"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Securities registered
pursuant to Section 12(b) of the Act:</p>

<p style="font-size: 10pt; text-align: center; text-indent: 0px; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%; border-collapse: collapse; text-align: left">
<tr style="vertical-align: bottom">
    <td style="border-bottom: #000000 1px solid; padding: 2px; text-align: center; width: 39%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
    of each class</b></span></td>
    <td style="padding: 2px; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: #000000 1px solid; padding: 2px; text-align: center; width: 20%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
    Symbol(s)</b></span></td>
    <td style="padding: 2px; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: #000000 1px solid; padding: 2px; text-align: center; width: 39%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 2px; text-align: center"><span id="xdx_90E_edei--Security12bTitle_c20221121__20221121_zMefb9tkxGLg" style="font: 10pt Times New Roman, Times, Serif">	<ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:Security12bTitle">Common
    Stock, par value $0.01 per share</ix:nonNumeric></span></td>
    <td style="padding: 2px"><b>&#160;</b></td>
    <td style="padding: 2px; text-align: center"><span id="xdx_901_edei--TradingSymbol_c20221121__20221121_zABJlnTXMf32" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" name="dei:TradingSymbol">SGRY</ix:nonNumeric></span></td>
    <td style="padding: 2px"><b>&#160;</b></td>
    <td style="padding: 2px; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--SecurityExchangeName_c20221121__20221121_zq6T1TJqRMGb"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company <span style="font-family: Wingdings"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20221121__20221121_zo2FU92cAfb1"><ix:nonNumeric contextRef="From2022-11-21to2022-11-21" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 14%"><span style="font-size: 10pt"><b>Item 1.01</b></span></td>
    <td style="font-size: 10pt; width: 86%"><span style="font-size: 10pt"><b>Entry into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On November 21, 2022, Surgery Partners, Inc. (the
 &#8220;<span style="text-decoration: underline">Company</span>&#8221;) effected a public offering of 23,469,388 shares of its common stock, $0.01 par value per share, at a price
to the public of $24.50 per share (the &#8220;<span style="text-decoration: underline">Public Offering</span>&#8221;). In addition, the Company granted the Underwriters an option
to purchase up to an additional 3,520,408 shares of its common stock at the public offering price. Subject to customary closing conditions,
the closing of the Public Offering is expected to take place on November 23, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In connection with the Public Offering, the Company
undertook a concurrent private placement (the &#8220;<span style="text-decoration: underline">Private Placement</span>&#8221;) of $225 million of its common stock to an affiliate
of its controlling shareholder (&#8220;<span style="text-decoration: underline">Bain Capital</span>&#8221;). In connection with the Private Placement, the Company and Bain Capital
entered into a stock purchase agreement (the &#8220;<span style="text-decoration: underline">Purchase Agreement</span>&#8221;) pursuant to which the Company has agreed to sell
and issue to Bain Capital, up to an aggregate of 9,183,673 shares of the Company&#8217;s common stock. The Private Placement is expected to close within 30 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The above description of the Purchase Agreement
is qualified in its entirety by reference to the Purchase Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K
and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 14%; font-size: 10pt"><span style="font-size: 10pt"><b>Item 3.02</b></span></td>
    <td style="width: 86%; font-size: 10pt"><span style="font-size: 10pt"><b>Unregistered Sales of Equity Securities.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The information contained above in Item 1.01 related
to the Private Placement is hereby incorporated by reference into this Item 3.02. The common stock to be issued in the Private Placement
has not been registered under the Securities Act of 1933, as amended and is being offered pursuant to the exemption provided in Section
4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 14%; font-size: 10pt"><span style="font-size: 10pt"><b>Item 8.01</b></span></td>
    <td style="width: 86%; font-size: 10pt"><span style="font-size: 10pt"><b>Other Events</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On November 21, 2022, the Company entered into
an underwriting agreement (the &#8220;<span style="text-decoration: underline">Underwriting Agreemen</span>t&#8221;) with BofA
Securities, Inc., J.P. Morgan Securities LLC, Barclays Capital Inc. and Jefferies LLC acting as representatives of the several
underwriters (the &#8220;<span style="text-decoration: underline">Underwriters</span>&#8221;), relating to the Public Offering. In
addition, the Company granted the Underwriters an option to purchase up to an additional 3,520,408 shares of common stock at the
same price per share as the public offering price. Subject to customary closing conditions, the closing of the Public Offering is
expected to take place on November 23, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Public Offering was made pursuant to the Company&#8217;s
effective automatic shelf registration statement on Form S-3, as amended (File No. 333-252399), and a related prospectus supplement dated
November 21, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The above description of the Underwriting Agreement is qualified in
its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 14%"><span style="font-size: 10pt"><b>Item 9.01</b></span></td>
    <td style="font-size: 10pt; width: 86%"><span style="font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: left; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit <br />
No.</b></span></td>
    <td style="text-align: left; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left; width: 91.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><a href="tm2230583d4_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><a href="tm2230583d4_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated November 21, 2022, among Surgery Partners, Inc. and BofA Securities, Inc., J.P. Morgan Securities LLC, Barclays Capital Inc. and Jefferies LLC, as representatives of the several underwriters.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><a href="tm2230583d4_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><a href="tm2230583d4_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Ropes &amp; Gray LLP.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><a href="tm2230583d4_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><a href="tm2230583d4_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated November 21, 2022, by and between, Surgery Partners, Inc. and Bain Capital Fund XI, L.P.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><a href="tm2230583d4_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><a href="tm2230583d4_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Ropes &amp; Gray LLP (included in Exhibit 5.1 above)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Date: November 22, 2022</span></td>
<td colspan="2" style="padding: 0.25pt"><b>Surgery Partners, Inc.</b></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0.25pt">&#160;</td>
<td colspan="2" style="padding: 0.25pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0.25pt; width: 50%">&#160;</td>
<td style="padding: 0.25pt; font-size: 10pt; width: 3%"><span style="font-size: 10pt">By:</span></td>
<td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; width: 47%"><span style="font-size: 10pt">/s/ David T. Doherty</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0.25pt">&#160;</td>
<td style="padding: 0.25pt">&#160;</td>
<td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Name: David T. Doherty</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0.25pt">&#160;</td>
<td style="padding: 0.25pt">&#160;</td>
<td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Title: Executive Vice President and Chief Financial Officer</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LNpNh7A3HSriFBlDfC0uSnFrRlqnfpJ/abchhkBI7j25QozEhta6QobzMs+gwLqplEPI8YqM5oLekW53CfiZ401bx8q4fv2BKXkGPROPpxd/752ttlgmIOeTUE4iCTJKZjEs9iLo9JTMVZdonFYVKFPCkalhjU7xe/hQqBcZqt990gnZajIJhGM5yB+IZBjBgVr1JL5byLJUBKO+ArFhejRdzMM6qmFVYe2z7ID+O/gC03pJBw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2230583d4_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Surgery Partners,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">23,469,388</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Underwriting Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">November&nbsp;21, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. Morgan Securities LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Barclays Capital Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jefferies LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Representatives of the <BR>
several Underwriters listed<BR> in Schedule 1 hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o BofA Securities,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One Bryant Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o J.P. Morgan Securities LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">383 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10179</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Barclays Capital Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">745 7th Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Jefferies LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">520 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surgery
Partners,&nbsp;Inc., a Delaware corporation (the &#8220;Company&#8221;), proposes to issue and sell to the several underwriters listed
in Schedule 1 hereto (the &#8220;Underwriters&#8221;), for whom you are acting as representatives (the &#8220;Representatives&#8221;),
an aggregate of </FONT>23,469,388 <FONT STYLE="font-size: 10pt">shares of common stock, par value $0.01 per share, of the Company (the
 &#8220;Underwritten Shares&#8221;) and, at the option of the Underwriters, up to an additional </FONT>3,520,408 <FONT STYLE="font-size: 10pt">shares
of common stock of the Company (the &#8220;Option Shares&#8221;). The Underwritten Shares and the Option Shares are herein referred to
as the &#8220;Shares&#8221;. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares
are referred to herein as the &#8220;Stock&#8221;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company hereby confirms its agreement with
the several Underwriters concerning the purchase and sale of the Shares, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Registration
Statement.</U> The Company has prepared and filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) under
the Securities Act of 1933, as amended, and the rules&nbsp;and regulations of the Commission thereunder (collectively, the
 &#8220;Securities Act&#8221;), a registration statement (File No.&nbsp;333-252399), including a prospectus, relating to the Shares.
Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to
Rule&nbsp;430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness
(&#8220;Rule&nbsp;430 Information&#8221;), is referred to herein as the &#8220;Registration Statement&#8221;; and as used herein,
the term &#8220;Preliminary Prospectus&#8221; means </FONT>each prospectus included in such registration statement (and any
amendments thereto) before effectiveness, any prospectus filed with the Commission pursuant to Rule&nbsp;424(a)&nbsp;under the
Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule&nbsp;430
Information, and the term &#8220;Prospectus&#8221; means the prospectus in the form first used (or made available upon request of
purchasers pursuant to Rule&nbsp;173 under the Securities Act) in connection with confirmation of sales of the Shares. Any reference
in this underwriting agreement (this &#8220;Agreement&#8221;) to the Registration Statement, any Preliminary Prospectus or the
Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of
Form&nbsp;S-3 under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary
Prospectus or the Prospectus, as the case may be, and any reference to &#8220;amend&#8221;, &#8220;amendment&#8221; or
 &#8220;supplement&#8221; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to
refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the
rules&nbsp;and regulations of the Commission thereunder (collectively, the &#8220;Exchange Act&#8221;) that are deemed to be
incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the
Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company expects to enter into definitive documentation
concurrently with the execution of this Agreement pursuant to which it will sell $225 million of shares of common stock of the Company
in a private placement to an affiliate of BCPE Seminole Holdings LP (collectively, &#8220;BCPE&#8221;) (the &#8220;Concurrent Private
Placement&#8221;). Completion of the transactions contemplated by this Agreement are not contingent on the completion of the Concurrent
Private Placement, however, the completion of the Concurrent Private Placement is contingent on the completion of the transactions contemplated
by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At or prior to the Applicable Time (as defined
below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the &#8220;Pricing
Disclosure Package&#8221;): a Preliminary Prospectus dated November&nbsp;21, 2022 and each &#8220;free-writing prospectus&#8221; (as defined
pursuant to Rule&nbsp;405 under the Securities Act) listed on Annex A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;Applicable Time&#8221; means 9:30 am, New York City time, on
November&nbsp;21, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Purchase
of the Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company agrees to issue and sell the Underwritten Shares to the several Underwriters as provided in this underwriting agreement (this
 &#8220;Agreement&#8221;), and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject
to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $23.6425 (the &#8220;Purchase
Price&#8221;) from the Company the respective number of Shares set forth opposite such Underwriter&#8217;s name in Schedule 1 hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the Company agrees to issue and sell
the Option Shares to the several Underwriters as provided in this Agreement, and the Underwriters, on the basis of the representations,
warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally
and not jointly, from the Company the Option Shares at the Purchase Price less an amount per share equal to any dividends or distributions
declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any Option Shares are to be purchased, the number
of Option Shares to be purchased by each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate
number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule
1 hereto (or such number increased as set forth in Section&nbsp;10 hereof) bears to the aggregate number of Underwritten Shares being
purchased from the Company by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares as the
Representatives in their sole discretion shall make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Underwriters may exercise the option to purchase
Option Shares at any time in whole, or from time to time in part, on or before the thirtieth day following the date of the Prospectus,
by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number of Option Shares as to which
the option is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date
and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth full business
day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions
of Section&nbsp;10 hereof). Any such notice shall be given at least two business days prior to the date and time of delivery specified
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company understands that the Underwriters intend to make a public offering of the Shares, and initially to offer the Shares on the terms
set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or
through any affiliate of an Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment
for the Shares shall be made by wire transfer in immediately available funds to the account specified by the Company to the Representatives
in the case of the Underwritten Shares, at the offices of Latham&nbsp;&amp; Watkins LLP at 10:00 A.M.&nbsp;New York City time on November&nbsp;23,
2022, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives
and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the
Representatives in the written notice of the Underwriters&#8217; election to purchase such Option Shares. The time and date of such payment
for the Underwritten Shares is referred to herein as the &#8220;Closing Date&#8221;, and the time and date for such payment for the Option
Shares, if other than the Closing Date, is herein referred to as the &#8220;Additional Closing Date&#8221;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payment for the Shares to be purchased on the Closing
Date or the Additional Closing Date, as the case may be, shall be made against delivery to the Representatives for the respective accounts
of the several Underwriters of the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, with
any transfer taxes payable in connection with the sale of such Shares duly paid by the Company. Delivery of the Shares shall be made through
the facilities of The Depository Trust Company (&#8220;DTC&#8221;) unless the Representatives shall otherwise instruct. The certificates
for the Shares will be made available for inspection and packaging by the Representatives at the office of DTC or its designated custodian
not later than 1:00 P.M., New York City time, on the business day prior to the Closing Date or the Additional Closing Date, as the case
may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the capacity of an arm&#8217;s
length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with
determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person.
Additionally, neither of the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax,
investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters
and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither
of the Representatives nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto. Any
review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating
to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. None of
the activities of the Representatives and the other Underwriters in connection with the transactions contemplated herein constitutes
a recommendation, investment advice or solicitation of any action by the Representatives and the other Underwriters with respect to any
entity or natural person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Preliminary
Prospectus.</I> No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary
Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the applicable
requirements of the Securities Act, and no Preliminary Prospectus, at the time of filing thereof, contained any untrue statement of a
material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any
statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company
in writing by such Underwriter through the Representatives expressly for use in any Preliminary Prospectus, it being understood and agreed
that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b)&nbsp;hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Pricing
Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date and as of the Additional
Closing Date, as the case may be, will not, contain any </FONT>untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U>
that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity
with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly
for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in Section&nbsp;7(b)&nbsp;hereof. No statement of material fact included in the Prospectus
has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that
is required to be included in the Prospectus has been omitted therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Issuer
Free Writing Prospectus. </I>Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company (including
its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved
or referred to and will not prepare, make, use, authorize, approve or refer to any &#8220;written communication&#8221; (as defined in
Rule&nbsp;405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication
by the Company or its agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &#8220;Issuer Free
Writing Prospectus&#8221;) other than (i)&nbsp;any document not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a)&nbsp;of
the Securities Act or Rule&nbsp;134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road
show and any other written communications approved in writing in advance by the Representatives. Each such Issuer Free Writing Prospectus
complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule&nbsp;433) filed
in accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in the Registration
Statement or the Pricing Disclosure Package, and, when taken together with the Preliminary Prospectus accompanying, or delivered prior
to delivery of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the
case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes
no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary
Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such
Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being
understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b)&nbsp;hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Registration
Statement and Prospectus.</I> The Registration Statement is an &#8220;automatic shelf registration statement&#8221; as defined under
Rule&nbsp;405 of the Securities Act that has been filed with the Commission not earlier than three years prior to the date hereof; and
no notice of objection of the Commission to the use of such registration statement or any post-effective amendment thereto pursuant to
Rule&nbsp;401(g)(2)&nbsp;under the Securities Act has been received by the Company. No order suspending the effectiveness of the Registration
Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act
against the Company or related to the offering of the Shares has been initiated or, to the knowledge of the Company, threatened by the
Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration
Statement and any such post-effective amendment complied and will comply in all material respects with the applicable requirements of
the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any
amendment or supplement thereto and as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus
will comply in all material respects with the applicable requirements of the Securities Act and will not contain any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any
statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company
in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any
amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists
of the information described as such in Section&nbsp;7(b)&nbsp;hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Incorporated
Documents.</I> The documents incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure
Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and
none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the
statements </FONT>therein, in the light of the circumstances under which they were made, not misleading; and any further documents
so filed and incorporated by reference in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such
documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Financial
Statements.</I> The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects
with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects
the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations
and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally
accepted accounting principles (&#8220;GAAP&#8221;) in the United States applied on a consistent basis throughout the periods covered
thereby, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material
respects the information required to be stated therein; and the other financial information included or incorporated by reference in the
Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company
and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby; all disclosures included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus regarding &#8220;non-GAAP
financial measures&#8221; (as such term is defined by the rules&nbsp;and regulations of Commission) comply with Regulation G of the Exchange
Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Material Adverse Change.</I> Since the date of the most recent financial statements of the Company included or incorporated by reference
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in the capital
stock (other than the issuance of shares of common stock of the Company upon exercise of stock options and warrants described as outstanding
in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure
Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution
of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change,
or any development involving a material prospective adverse change, in or affecting the business, properties, management, financial position,
stockholders&#8217; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii)&nbsp;neither
the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business)
that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that
is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its subsidiaries has sustained
any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from
fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action,
order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Organization
and Good Standing.</I> The Company and each of its subsidiaries have been duly organized and are validly existing and in good standing
under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction
in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and
have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged,
except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate,
reasonably be expected to have a material adverse effect on the business, properties, management, financial position, stockholders&#8217;
equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of
its obligations under this Agreement (a &#8220;Material Adverse Effect&#8221;). The subsidiaries listed in Schedule 2 to this Agreement
are the only significant subsidiaries of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Capitalization. </I>The
Company has the authorized, issued and outstanding shares of capital stock as set forth or incorporated by reference in the
Registration Statement, the Pricing Disclosure Package and </FONT>the Prospectus under the caption &#8220;Capitalization&#8221;
(except for subsequent issuances, if any, pursuant to reservations, agreements or employee benefit plans referred to in the Pricing
Disclosure Package and the Prospectus or pursuant to the exercise of convertible securities or options referred to in the Pricing
Disclosure Package and the Prospectus). The outstanding shares of capital stock of the Company have been duly authorized and validly
issued and are fully paid and non&#45;assessable. None of the outstanding shares of capital stock of the Company were issued in
violation of the preemptive or other similar rights of any securityholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Due
Authorization.</I> The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations
hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and
the consummation by it of the transactions contemplated hereby has been duly and validly taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Underwriting
Agreement. </I> This Agreement has been duly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>The
Shares. </I>The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered
and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform in all material
respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and the issuance
of the Shares is not subject to any preemptive or similar rights that have not been duly waived or satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Description
of the Underwriting Agreement.</I> This Agreement conforms in all material respects to the description thereof contained in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Violation or Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or by-laws or similar
organizational documents; (ii)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained
in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which
any such entity is a party or by which it or any of them may be bound or to which any of the properties or assets of any of the Company
or any subsidiary is subject (collectively, &#8220;Agreements and Instruments&#8221;), except for such defaults that would not, individually
or in the aggregate, be reasonably expected to result in a Material Adverse Effect, or (iii)&nbsp;in violation of any law, statute, rule,
regulation, judgment, order, writ or decree (collectively, &#8220;Applicable Law&#8221;) of any entity or body exercising executive,
legislative, judicial, regulatory or administrative functions of United States federal, state, local or municipal government, including
any authority or other quasi-governmental entity established by and to which authority shall have been delegated by a governmental body,
or other authority, body or agency, in each case, having jurisdiction over the Company or any of its subsidiaries or any of their respective
properties, assets or operations (each, a &#8220;Governmental Entity&#8221;), except for such violations that would not, individually
or in the aggregate, be reasonably expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Conflicts. </I>The execution, delivery and performance of this Agreement and compliance by the Company with its obligations hereunder
have been duly authorized by all necessary corporate action of the Company and do not and will not, whether with or without the giving
of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under,
or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or any subsidiary
pursuant to the Agreement, except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would
not, individually or in the aggregate, be reasonably expected to result in a Material Adverse Effect, nor will such action result in
any violation of (A)&nbsp;the applicable charter or bylaws or similar organizational documents of the Company or any subsidiary or (B)&nbsp;any
law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity, except, with respect to clause (B), such
violations as would not reasonably be expected to result in a Material Adverse Effect. As used herein, a &#8220;Repayment Event&#8221;
means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on
such holder&#8217;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by
the Company or any subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Consents Required.</I> No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator
or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement,
the issuance and sale of the Shares and the consummation of the transactions contemplated by this Agreement, or for the completion
of the Concurrent Private Placement, except for the registration of the Shares under the Securities Act and such consents,
approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory </FONT>Authority,&nbsp;Inc.
(&#8220;FINRA&#8221;) and under applicable state securities laws in connection with the purchase and distribution of the Shares by
the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Absence
of Proceedings.</I> Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no
action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to the knowledge of the
Company, threatened, against or affecting the Company or any of its subsidiaries, which would be reasonably expected to result in a Material
Adverse Effect, or which would be reasonably expected to materially and adversely affect their respective properties or assets or the
performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the
Company or any subsidiary is a party or of which any of their respective properties or assets is the subject which are not described in
the Pricing Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, would not be reasonably
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Independent
Accountants</I>. Deloitte&nbsp;&amp; Touche LLP, who have certified certain financial statements of the Company and its subsidiaries,
is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules&nbsp;and
regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Title
to Properties</I>. The Company and its subsidiaries have good and marketable title to all real property owned by them and good title to
all other properties owned by them that are material to the Company, in each case, free and clear of all mortgages, pledges, liens, security
interests, claims, restrictions or encumbrances of any kind except such as (i)&nbsp;are described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus or (ii)&nbsp;do not, individually or in the aggregate, materially affect the value of such property
and do not materially interfere with the use made and proposed to be made of such property by the Company or any of its subsidiaries;
and all of the leases and subleases material to the business of the Company and the subsidiaries, considered as one enterprise, under
which the Company or any of its subsidiaries holds properties described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, are in full force and effect, and neither the Company nor any such subsidiary has any notice of any material claim
of any sort that has been asserted by anyone adverse to the rights of the Company or any subsidiary under any of the leases or subleases
mentioned above, or affecting or questioning the rights of the Company or such subsidiary to the continued possession of the leased or
subleased premises under any such lease or sublease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Intellectual
Property Rights.</I> The Company and its subsidiaries own or possess, or can acquire on reasonable terms, adequate patents, patent rights,
licenses, inventions, copyrights, know&#45;how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures), trademarks, service marks, trade names or other intellectual property (collectively, &#8220;Intellectual
Property&#8221;) necessary to carry on the business now operated by them, except for those the failure to own or have such legal right
to use would not be reasonably expected to result in a Material Adverse Effect, and neither the Company nor any of its subsidiaries has
received written notice of any infringement of or conflict with asserted rights of others with respect to any Intellectual Property or
of any facts or circumstances which would render any Intellectual Property invalid or inadequate to protect the interest of the Company,
or any of its subsidiaries therein, which infringement or conflict (if the subject of any unfavorable decision, ruling or finding) or
invalidity or inadequacy, individually or in the aggregate, would be reasonably expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on
the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries,
on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that
is not so described in such documents and in the Pricing Disclosure Package.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Investment
Company Act</I>. The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds
thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or the offering and sale of shares
of the Company&#8217;s common stock in the Concurrent Private Placement, will not be required to register as an &#8220;investment company&#8221;
or an entity &#8220;controlled&#8221; by an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940,
as amended, and the rules&nbsp;and regulations of the Commission thereunder (collectively, the &#8220;Investment Company Act&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Tax
Law Compliance.</I> All federal, state, local and foreign tax returns of the Company and its subsidiaries required by law to be filed
have been filed insofar as the failure to file such returns would not, individually or in the aggregate, by reasonably expected to result
in a Material Adverse Effect, and all taxes due and payable, and any related or similar assessment, fine or penalty levied against the
Company and its subsidiaries have been paid, other than taxes that are being contested in good faith and as to which adequate reserves
have been established by the Company in accordance with GAAP, except in any case in which the failure to pay would not, individually or
in the aggregate, be reasonably expected to result in a Material Adverse Effect. The charges, accruals and reserves on the financial statements
of the Company in respect of any income, corporation, franchise and other material tax liability for any years not finally determined
have been established in accordance with GAAP and are adequate to meet any assessments or re-assessments for additional income tax for
any years not finally determined, except to the extent of any inadequacy that would not, individually or in the aggregate, be reasonably
expected to result in a Material Adverse Effect. No tax deficiency has been determined adversely to the Company or any of its subsidiaries,
nor does the Company have any knowledge of any tax deficiencies that have been, or would reasonably be expected to be, asserted against
the Company or any subsidiary that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Possession
of Licenses and Permits.</I> The Company, its subsidiaries and the joint ventures set forth in Schedule 3 hereto (the &#8220;JVs&#8221;)
possess such certificates, consents, exemptions, orders, licenses, authorities, accreditations, provider or supplier numbers, certificates
of need or permits issued by the appropriate Governmental Entities (collectively, &#8220;Permits&#8221;) necessary to conduct the business
now owned, operated or managed by them including but not limited to such Permits as are required (i)&nbsp;under Health Care Laws (as defined
herein) and (ii)&nbsp;with respect to those facilities owned, operated or managed by the Company or any of its subsidiaries or the JVs
that participate in Medicare, Medicaid or any other local, state or federal government health care program, to receive reimbursement thereunder,
except where the failure to so possess would not be reasonably expected to result in a Material Adverse Effect. The Company, its subsidiaries,
and the JVs are in compliance with the terms and conditions of all Permits, except where the failure to so comply would not be reasonably
expected to result in a Material Adverse Effect. All of the Permits are valid and in full force and effect, except when the invalidity
of such Permits or the failure of such Permits to be in full force and effect would not be reasonably expected to result in a Material
Adverse Effect. None of the Company or any of its subsidiaries or the JVs has received written notice of proceedings relating to the revocation
or modification of any such Permit that, if the subject of an unfavorable decision, ruling or finding, would be reasonably expected to
result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Labor Disputes.</I> No labor dispute with the employees of the Company or, to the knowledge of the Company, its subsidiaries exists or,
to the knowledge of the Company, is imminent, except as would not be reasonably expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Certain
Environmental Matters</I>. Except as described in the Registration Statement, the Prospectus and the Pricing Disclosure Package or as
would not, individually or in the aggregate, be reasonably expected to result in a Material Adverse Effect, (A)&nbsp;neither the Company
nor any of its subsidiaries is in violation of any applicable federal, state, local or foreign statute, law, rule, regulation, ordinance,
code, policy or rule&nbsp;of common law or any judicial or administrative interpretation thereof, including any judicial or administrative
order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation,
ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations
relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances,
petroleum or petroleum products, asbestos-containing materials or mold (collectively, &#8220;Hazardous Materials&#8221;) or to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#8220;Environmental
Laws&#8221;), (B)&nbsp;the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental
Laws and are each in compliance with their requirements, (C)&nbsp;there are no pending or, to the knowledge of the Company, threatened
administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation,
investigations or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (D)&nbsp;to the knowledge
of the Company, there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation,
or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company or any of its subsidiaries
relating to Hazardous Materials or any Environmental Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Compliance
with ERISA</I>. Except as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect, (i)&nbsp;each
 &#8220;employee benefit plan&#8221; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations
and published interpretations thereunder (collectively, &#8220;ERISA&#8221;)), whether or not subject to ERISA, for which the Company
or any member of its &#8220;Controlled Group&#8221; (defined as any organization which is a member of a controlled group of corporations
within the meaning of Section&nbsp;414 of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations
thereunder (the &#8220;Code&#8221;)) has any liability (each, a &#8220;Plan&#8221;) has been maintained in compliance with its terms and
with the requirements of all applicable statutes, rules&nbsp;and regulations, including ERISA and the Code; (ii)&nbsp;neither the Company
nor any member of its Controlled Group has in the past six (6)&nbsp;years incurred, or reasonably expects to incur, any liability under
Title IV of ERISA in respect of a Plan (including a &#8220;multiemployer plan,&#8221; within the meaning of Section&nbsp;4001(c)(3)&nbsp;of
ERISA); (iii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code is so qualified and nothing has
occurred, whether by action or by failure to act, which would cause the loss of such qualification; (iv)&nbsp;there is no pending audit
or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other
governmental agency with respect to any Plan; and (v)&nbsp;neither the Company nor any subsidiary has incurred any liability for any prohibited
transaction, the failure of any Plan to meet the minimum funding standards required by law, including by ERISA or the Code, or any complete
or partial withdrawal liability with respect to any Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Disclosure
Controls</I>. The Company and its subsidiaries maintain an effective system of &#8220;disclosure controls and procedures&#8221; (as defined
in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to
ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the Commission&#8217;s rules&nbsp;and forms, including controls
and procedures designed to ensure that such information is accumulated and communicated to the Company&#8217;s management as appropriate
to allow timely decisions regarding required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness
of their disclosure controls and procedures as required by Rule&nbsp;13a-15 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Accounting
Controls.</I> The Company and its subsidiaries maintain systems of &#8220;internal control over financial reporting&#8221; (as defined
in Rule&nbsp;13a-15(f)&nbsp;of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under
the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable
assurance that (i)&nbsp;transactions are executed in accordance with management&#8217;s general or specific authorizations; (ii)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability;
(iii)&nbsp;access to assets is permitted only in accordance with management&#8217;s general or specific authorization; (iv)&nbsp;the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences and (v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration
Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information called for in all material respects and is
prepared in accordance with the Commission&#8217;s rules&nbsp;and guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Insurance.
</I>The Company and its subsidiaries carry or are entitled to the benefits of insurance, with financially sound and reputable insurers,
in such amounts and covering such risks as is generally maintained by similarly sized and situated companies of established repute engaged
in the same or similar business, and all such insurance is in full force and effect, except where failure to carry such insurance would
not be reasonably expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Cybersecurity;
Data Protection. </I> The Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems,
networks, hardware, software, websites, applications, and databases (collectively, &#8220;IT Systems&#8221;) are adequate for, and
operate and perform in all material respects as required in connection with the operation of the business of the Company and its
subsidiaries as currently conducted, and free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware
and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies,
procedures, and safeguards designed to maintain and protect their material confidential information and the security of all IT
Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&#8220;Personal
Data&#8221;)) used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of
or accesses to same, except as would not, individually or in the aggregate, </FONT>reasonably be expected to have a Material Adverse
Effect. The Company and its subsidiaries have implemented business continuity / disaster recovery plans and technology consistent
with industry standards and practice. The Company and its subsidiaries are presently in material compliance with all applicable laws
or statutes and all judgments, orders, rules&nbsp;and regulations of any court or arbitrator or governmental or regulatory
authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to
the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification including the
Data Privacy and Security Laws (&#8220;Data Protection Requirements&#8221;), except as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. To ensure compliance with the Data Protection Requirements, the Company
and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material
respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling, and analysis of Personal Data (the &#8220;Policies&#8221;). The Company and its subsidiaries have at all times made all
material disclosures to patients or other individuals required by applicable Data Protection Requirements, and none of such
disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable
Data Protection Requirements in any material respect. The execution, delivery and performance of this Agreement or any other
agreement referred to in this Agreement will not result in a breach or violation of any Data Protection Requirements or Policies,
except where such breach or violation would not, individually or in the aggregate, have a Material Adverse Effect. The Company
further certifies that neither it nor any subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or
relating to, or actual or potential violation of, any of the Data Protection Requirements, and has no knowledge of any event or
condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole
or in part, any investigation, remediation, or other corrective action pursuant to any Data Protection Requirement; or (iii)&nbsp;is
a party to any order, decree, or agreement that imposes any obligation or liability by any governmental authority under any Data
Protection Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Foreign
Corrupt Practices Act</I>. None of the Company or any of its subsidiaries (including any JV controlled by the Company), any of the directors
and officers thereof, or any controlled affiliate thereof, or, to the knowledge of the Company, any JV in which the Company holds a minority
interest, non-controlled affiliate, agent, employee, or other person acting on behalf of the Company, any of its subsidiaries or any of
the JVs is aware of, has taken or will take any action, directly or indirectly, that would result in a violation by such persons of the
Foreign Corrupt Practices Act of 1977, as amended, and the rules&nbsp;and regulations thereunder (the &#8220;FCPA&#8221;) or similar law
of any other relevant jurisdiction, including, without limitation, making use of the mails or any means or instrumentality of interstate
commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property,
gift, promise to give, or authorization of the giving of anything of value to any &#8220;foreign official&#8221; (as such term is defined
in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the
FCPA and the Company, it subsidiaries (including any JV controlled by the Company) and any affiliates thereof, and to the knowledge of
the Company, any JV in which the Company holds a minority interest, have conducted their businesses in compliance with the FCPA and have
instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued
compliance therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Compliance
with Anti-Money Laundering Laws</I>. The operations of the Company, its subsidiaries (including any JV controlled by the Company) and,
to the knowledge of the Company, the JVs in which the Company holds a minority interest, are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all applicable jurisdictions, the rules&nbsp;and regulations thereunder and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &#8220;Money Laundering
Laws&#8221;); and no action, suit or proceeding by or before any Governmental Entity involving the Company or any of its subsidiaries
(including any JV controlled by the Company) or, to the knowledge of the Company, the JVs in which the Company holds a minority interest,
with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>OFAC. </I>None
of the Company, any of its subsidiaries (including any JV controlled by the Company) or any of their respective directors and
officers, or any of the Company&#8217;s controlled affiliates, or, to the knowledge of the Company, any JVs in which the Company
holds a minority interest, non-controlled affiliate, agent, employee or representative of the Company or any of the subsidiaries or
JVs is an individual or en</FONT>tity (&#8220;Person&#8221;), or is owned or controlled by a Person, currently the subject or
target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department
of the Treasury&#8217;s Office of Foreign Assets Control (&#8220;OFAC&#8221;), the United Nations Security Council
(&#8220;UNSC&#8221;), the European Union, Her Majesty&#8217;s Treasury (&#8220;HMT&#8221;), or other relevant sanctions authority
(collectively, &#8220;Sanctions&#8221;), nor located, organized or resident in a country or territory that is the subject or target
of Sanctions (including, without limitation, the Crimea region of Ukraine, the so-called Donetsk People&#8217;s Republic, the
so-called Luhansk People&#8217;s Republic, Cuba,&nbsp;Iran, North Korea, Sudan and Syria); the Company will not directly or
indirectly use the proceeds of the sale of the Shares or of the sale of common stock in the Concurrent Private Placement, or lend,
contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any
activities of or business with any Person, or in any country or territory, that, at the time of such funding, is the subject or
target of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the
transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; and for the past five years, the Company and its
subsidiaries and JVs have not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or
transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject
of Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Restrictions on Subsidiaries</I>. No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or
other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on
such subsidiary&#8217;s capital stock or similar ownership interest, from repaying to the Company any loans or advances to such subsidiary
from the Company or from transferring any of such subsidiary&#8217;s properties or assets to the Company or any other subsidiary of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Broker&#8217;s Fees.</I> Neither the Company nor any of its affiliates has engaged any broker, finder, commission agent or other person
(other than the Underwriters) in connection with the offering of Shares contemplated hereby, and neither the Company nor any of its affiliates
is under any obligation to pay any broker&#8217;s fee or commission in connection with the offering of Shares contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Registration Rights</I>. No person has the right to require the Company or any of its subsidiaries to register any securities for sale
under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Stabilization.</I> Neither the Company nor any of its subsidiaries or affiliates has taken, directly or indirectly, any action designed
to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Margin
Rules</I>. Neither the issuance, sale and delivery of the Shares nor the application of the proceeds thereof by the Company as described
in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board
of Governors of the Federal Reserve System or any other regulation of such Board of Governors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Sarbanes-Oxley
Act</I>. There is and has been no failure on the part of the Company or any of the Company&#8217;s directors or officers, in their capacities
as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules&nbsp;and regulations promulgated
in connection therewith (the &#8220;Sarbanes-Oxley Act&#8221;), including Section&nbsp;402 related to loans and Sections 302 and 906 related
to certifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Status
under the Securities Act</I>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest
time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule&nbsp;164(h)(2)&nbsp;under
the Securities Act) of the Shares and at the date hereof, the Company was not and is not an &#8220;ineligible issuer,&#8221; and is a
well-known seasoned issuer, in each case as defined in Rule&nbsp;405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Third-Party
Payors</I>. Except as described in the Registration Statement, the Prospectus and the Pricing Disclosure Package or as would not,
individually or in the aggregate, be reasonably expected to result in a Material Adverse Effect, the accounts receivable of the
Company and each of its subsidiaries and JVs have been adjusted to reflect contractual allowances provided to third-party payors,
private insurance companies, health maintenance organizations, preferred provider organizations, alternative delivery systems,
managed care systems, government contracting agencies and other third-party payors and the rates established by governmental payors,
including Medicare, Medicaid and, in some instances, for workers&#8217; compensation claims. In particu</FONT>lar, accounts
receivable relating to such third-party payors do not exceed amounts any obligee is entitled to receive under any capitation
arrangement, fee schedule, discount formula, cost-based reimbursement or other adjustment or limitation to its usual charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Compliance
with Health Care Laws</I>. Except as described in the Registration Statement, the Prospectus and the Pricing Disclosure Package or except
as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect, each of the Company, its subsidiaries
and the JVs is, and at all times has been, in compliance with all applicable Health Care Laws, and has not engaged in activities which
are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or
any other state health care program or federal health care program. For purposes of this Agreement, &#8220;Health Care Laws&#8221; means
all Applicable Laws of any Governmental Entity pertaining to health care regulatory matters applicable to the operations of the Company,
its subsidiaries or its JVs, including (i)&nbsp;federal, state and local health care related fraud and abuse laws, including, without
limitation, state corporate practice of medicine laws and regulations, state professional fee-splitting laws and regulations, state workers&#8217;
compensation laws and regulations, the Anti-Kickback Statute (42 U.S.C. Section&nbsp;1320a-7b(b)), the Stark Law (42 U.S.C. Section&nbsp;1395nn),
the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal
laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal
provisions under HIPAA (as defined below), the exclusion laws (42 U.S.C. &sect; 1320a-7), the civil monetary penalties law (42 U.S.C.
 &sect; 1320a-7a), any applicable state fraud and abuse prohibitions, including those that apply to all payors (governmental, commercial
insurance and self-payors), each as amended, and the implementing rules&nbsp;and regulations promulgated pursuant to such statutes; (ii)&nbsp;Medicare
(Title XVIII of the Social Security Act); (iii)&nbsp;Medicaid (Title XIX of the Social Security Act), and the regulations promulgated
thereunder; (iv)&nbsp;(a)&nbsp;the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &sect;&sect; 1320d-1329d-8,
as amended by the Health Information Technology for Economic and Clinical Health Act, enacted as Title XIII of the American Recovery and
Reinvestment Act of 2009, Public Law 111-5 (&#8220;HIPAA&#8221;); (b)&nbsp;all applicable implementing laws and regulations; and (c)&nbsp;any
similar state and local Applicable Laws regarding data protection, data processing, data privacy, data security and/or the collection,
use, storage, disclosure or cross-border transfer of personal data and information, including protected health information (collectively,
including HIPAA, the &#8220;<U>Data Privacy and Security Laws</U>&#8221;); (v)&nbsp;any state and federal controlled substance and drug
diversion laws, including the Federal Controlled Substances Act (21 U.S.C. &sect; 801, <I>et seq.</I>) and the regulations promulgated
thereunder; (vi)&nbsp;the Clinical Laboratory Improvement Amendments of 1988, 42 U.S.C. &sect;&nbsp;263a <I>et seq</I>.; (vii)&nbsp;any
Applicable Law pertaining to or regulating the provision or administration of, or payment for, healthcare products and services (such
services include physician and allied professional services and related ancillary services); (viii)&nbsp;and Applicable Law regulating
the ownership or operation of a health care facility or business, or assets used in connection therewith, including licensing, certification
and/or accreditation requirements; and (ix)&nbsp;any and all other health care laws and regulations, each as amended from time to time,
applicable to the operations of the Company, its subsidiaries or its JVs. Except as described in the Registration Statement, the Prospectus
and the Pricing Disclosure Package, none of the Company, any subsidiary or any of the JVs has received written notice from any Governmental
Entity of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action alleging that any of the
Company, the subsidiaries or the JVs is in material violation of any Health Care Laws, and, to the Company&#8217;s knowledge, no such
claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. Except as described in
the Registration Statement, the Prospectus and the Pricing Disclosure Package, none of the Company, any subsidiary or any of the JVs is
a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring
agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any Governmental Entity.
Additionally, none of the Company, its subsidiaries, or the JVs nor any of their respective employees, officers or directors has been
excluded, suspended or debarred from participation in any U.S. federal health care program or is subject to a governmental inquiry, investigation,
proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Program
Participation</I>. Except as described in the Registration Statement, the Prospectus and the Pricing Disclosure Package, the
Company, its subsidiaries, and the JVs, as applicable, meet all material requirements of participation of the Programs, are a party
to valid participation agreements for payment by such Programs, and has not at any time violated in any material respects any
condition of participation, condition of payment or any rule, regulation or policy or standard of any Program. None of the Company,
its subsidiaries or the JVs, has received notice from any of the Programs of any pending or threatened investigations that would </FONT>result
in exclusion or debarment from any such Programs or the termination of any Program participation or payor agreement.
 &#8220;<U>Programs</U>&#8221; shall mean Medicare, Medicaid, and any other local, state or federal health care program as well as
other third-party payor programs, including, but not limited to private insurance companies, health maintenance organizations,
preferred provider organizations, alternative delivery systems, and managed care systems, that the Company, its subsidiaries and the
JVs, as applicable, participate in or has contracts with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Program
Claims and Filings</I>. Except as described in the Registration Statement, the Prospectus and the Pricing Disclosure Package or except
as would not be reasonably expected to result in, individually or in the aggregate, a Material Adverse Effect, to the Company&#8217;s
knowledge, all reports, data, and information required to be filed by the Company, its subsidiaries, and the JVs in connection with any
Program have been timely filed and were true and complete at the time filed (or were corrected in or supplemented by a subsequent filing).
Except as described in the Registration Statement, the Prospectus and the Pricing Disclosure Package, none of the Company, its subsidiaries
and the JVs has submitted to any Program any false or fraudulent claim for payment. Except as described in the Registration Statement,
the Prospectus and the Pricing Disclosure Package, there are no claims, actions or appeals pending (and the Company, its subsidiaries,
and the JVs have not made any filing or submission that would result in any claims, actions or appeals) before any Governmental Entity
with respect to any Program reports or claims filed by the Company, or any of its subsidiaries or the JVs on or before the date hereof,
or with respect to any disallowances by any Governmental Entity in connection with any audit or any claims that, if adversely determined,
which would be reasonably expected to result in, individually or in the aggregate, a Material Adverse Effect. Except as described in the
Registration Statement, the Prospectus and the Pricing Disclosure Package, no validation review or program integrity review related to
the Company, or any of its subsidiaries or the JVs has been conducted by any governmental entity in connection with any Program within
the past three (3)&nbsp;years which, if determined adversely to the Company or any of its respective subsidiaries or JVs, has had, or
would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, and to the Company&#8217;s knowledge,
no such reviews are scheduled, pending, threatened against or affecting the Company or any of its subsidiaries or JVs. Except in the ordinary
course of business or as set forth in or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, there are no material suspensions, offsets or recoupments of any Program being sought, requested or claimed, or to the knowledge
of the Company, threatened against the Company, its subsidiaries or the JVs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Company
Providers</I>. The Company and each of its subsidiaries and JVs is in material compliance with all Applicable Laws regarding the selection,
deselection, and credentialing of contracted or employed healthcare providers, including, but not limited to, verification of licensing
status and eligibility for reimbursement under the Programs. Except as has not had, and would not be reasonably expected to result in,
individually or in the aggregate, a Material Adverse Effect, all of the Company&#8217;s, its subsidiaries&#8217; and the JVs&#8217; contracted
or employed healthcare providers are properly licensed and hold appropriate clinical privileges, as applicable, for the services that
they provide, and, with respect to providers that perform services eligible for reimbursement under any Program, are not debarred or excluded
from any such Program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Further
Agreements of the Company</U>. The Company covenants and agrees with each Underwriter that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Required
Filings.</I> The Company will file the final Prospectus with the Commission within the time periods specified by Rule&nbsp;424(b)&nbsp;and
Rule&nbsp;430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule&nbsp;433
under the Securities Act; and the Company will file promptly all reports and any definitive proxy or information statements required to
be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act subsequent to
the date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the
Shares; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered)
to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement
in such quantities as the Representatives may reasonably request. The Company will pay the registration fee for this offering within the
time period required by Rule&nbsp;456(b)(1)&nbsp;under the Securities Act (without giving effect to the proviso therein) and in any event
prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Delivery
of Copies.</I> The Company will deliver, without charge, (i)&nbsp;to the Representatives, three signed copies of the Registration
Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and
documents incorporated by reference therein; and (ii)&nbsp;to each Underwriter (A)&nbsp;a conformed copy of the Registration
Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as
defined below), as many copies of </FONT>the Prospectus (including all amendments and supplements thereto and documents incorporated
by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the
term &#8220;Prospectus Delivery Period&#8221; means such period of time after the first date of the public offering of the Shares as
in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required
to be delivered but for Rule&nbsp;172 under the Securities Act) in connection with sales of the Shares by any Underwriter or
dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Amendments
or Supplements,&nbsp;Issuer Free Writing Prospectuses.</I> Before making, preparing, using, authorizing, approving, referring to or filing
any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure
Package or the Prospectus, whether before or after the time that the Registration Statement becomes effective, the Company will furnish
to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement
for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such
proposed amendment or supplement to which the Representatives reasonably object.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Notice
to the Representatives.</I> The Company will advise the Representatives promptly, and confirm such advice in writing, (i)&nbsp;when the
Registration Statement has become effective upon filing; (ii)&nbsp;when any amendment to the Registration Statement has been filed or
becomes effective; (iii)&nbsp;when any supplement to the Pricing Disclosure Package, the Prospectus, or any Issuer Free Writing Prospectus
or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the
Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to
the Registration Statement or any other request by the Commission for any additional information; (v)&nbsp;of the issuance by the Commission
or any other governmental or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing
or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or the initiation or threatening
of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any event or development
within the Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package or any Issuer Free Writing
Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package
or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading; and (vii)&nbsp;of the receipt by the Company of
any notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to
Rule&nbsp;401(g)(2)&nbsp;under the Securities Act; and (viii)&nbsp;of the receipt by the Company of any notice with respect to any suspension
of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such
purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of
the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the
Prospectus or suspending any such qualification of the Shares and, if any such order is issued, will use its reasonable best efforts to
obtain as soon as possible the withdrawal thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: a1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Ongoing
Compliance.</I> (1)&nbsp;If during the Prospectus Delivery Period (i)&nbsp;any event or development shall occur or condition shall
exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when
the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to
comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph
(c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate
such amendments or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference
therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed
with the Commission and incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus
is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at any time prior to the
Closing Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure
Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances existing when the </FONT>Pricing Disclosure
Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Pricing Disclosure
Package to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to
paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as
the Representatives may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with
the Commission and incorporated by reference therein) as may be necessary so that the statements in the Pricing Disclosure Package
as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered
to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Blue
Sky Compliance.</I> The Company will qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions
as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of
the Shares; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as
a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent
to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise
so subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Earning
Statement. </I>The Company will make generally available to its security holders and the Representatives as soon as practicable an earning
statement that satisfies the provisions of Section&nbsp;11(a)&nbsp;of the Securities Act and Rule&nbsp;158 of the Commission promulgated
thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the &#8220;effective
date&#8221; (as defined in Rule&nbsp;158) of the Registration Statement; provided that the Company will be deemed to have furnished such
statements to its security holders and the Representatives to the extent that they are filed on the Commission&#8217;s Electronic Data
Gathering, Analysis and Retrieval system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Clear
Market.</I> For a period of 45 days after the date of the Prospectus, the Company will not (i)&nbsp;offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend,
or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Commission a registration statement under
the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly
disclose the intention to undertake any of the foregoing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole
or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described
in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the
prior written consent of any one of BofA Securities,&nbsp;Inc. (&#8220;<U>BofA</U>&#8221;), J.P. Morgan Securities LLC (&#8220;<U>J.P.
Morgan</U>&#8221;), Barclays Capital Inc. (&#8220;<U>Barclays</U>&#8221;), and Jefferies LLC (&#8220;<U>Jefferies</U>&#8221;), other than
the Shares to be sold hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">The restrictions described above do not
apply to (i)&nbsp;the issuance of shares of Stock or securities convertible into or exercisable for shares of Stock pursuant to the conversion
or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement
of RSUs (including net settlement), in each case outstanding on the date of this Agreement and described in the Prospectus; (ii)&nbsp;grants
of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of Stock or securities convertible
into or exercisable or exchangeable for shares of Stock (whether upon the exercise of stock options or otherwise) to the Company&#8217;s
employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the Closing
Date and described in the Prospectus, provided that such recipients enter into a lock-up agreement with the Underwriters; (iii)&nbsp;the
filing of any registration statement on Form&nbsp;S-8 relating to securities granted or to be granted pursuant to any plan in effect on
the date of this Agreement and described in the Prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic
transaction; (iv)&nbsp;the issuance of shares of common stock in the Concurrent Private Placement; or (v)&nbsp;the filing of any registration
statement on Form&nbsp;S-4 or other appropriate form with respect to the issuance by the Company of shares of any class of the common
stock of the Company or any securities convertible into or exercisable or exchangeable for shares of any class of the Company&#8217;s
common stock in connection with future business combinations or acquisitions (or the entering into of an acquisition or similar agreement
with respect thereto); <I>provided </I>that, in the case of clause (iv), the aggregate number of shares of common stock issued in connection
with, all such business combinations or acquisitions does not exceed 5% of the aggregate number of shares of common stock outstanding
immediately following the offering of shares pursuant to this Agreement and the recipient of the shares of common stock agrees in writing
to be bound by the same terms described in the &#8220;lock-up&#8221; agreement described in Section&nbsp;6(m)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Use
of Proceeds.</I> The Company will apply the net proceeds from the sale of the Shares herein and in the Concurrent Private Placement as
described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#8220;Use of Proceeds&#8221;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Stabilization.</I> Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly, without giving effect to
activities by the Underwriters, any action designed to or that could reasonably be expected to cause or result in any stabilization or
manipulation of the price of the Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Exchange
Listing.</I> The Company will use its reasonable best efforts to list for quotation the Shares on the Nasdaq Global Market (the &#8220;Nasdaq
Market&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Reports.</I>
During a period of three years from the date of this Agreement, the Company will furnish to the Representatives, as soon as commercially
reasonable after the date they are available, copies of all reports or other communications (financial or other) furnished to holders
of the Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities
exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements
to the Representatives to the extent they are filed on the Commission&#8217;s Electronic Data Gathering, Analysis, and Retrieval system,
or any successor to such system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Record
Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free Writing
Prospectus that is not filed with the Commission in accordance with Rule&nbsp;433 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Shelf
Renewal</I>. If immediately prior to the third anniversary (the &#8220;Renewal Deadline&#8221;) of the initial effective date of the Registration
Statement, any of the Shares remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already
done so and is eligible to do so, a new automatic shelf registration statement relating to the Shares, in a form satisfactory to the Representatives.
If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if
it has not already done so, file a new shelf registration statement relating to the Shares, in a form satisfactory to the Representatives,
and will use its reasonable best efforts to cause such registration statement to be declared effective within 180 days after the Renewal
Deadline. The Company will take all other action necessary or appropriate to permit the issuance and sale of the Shares to continue as
contemplated in the expired registration statement relating to the Shares. References herein to the Registration Statement shall include
such new automatic shelf registration statement or such new shelf registration statement, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Agreements of the Underwriters</U>.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each Underwriter hereby represents
and agrees that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">It
has not and will not use, authorize use of, refer to or participate in the planning for use of, any &#8220;free writing prospectus&#8221;,
as defined in Rule&nbsp;405 under the Securities Act (which term includes use of any written information furnished to the Commission by
the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than
(i)&nbsp;a free writing prospectus that contains no &#8220;issuer information&#8221; (as defined in Rule&nbsp;433(h)(2)&nbsp;under the
Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed
Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c)&nbsp;or
Section&nbsp;4(c)&nbsp;above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such underwriter
and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii), an &#8220;Underwriter
Free Writing Prospectus&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">It
has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final terms
of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; <I>provided</I>
that Underwriters may use a term sheet substantially in the form of Annex B hereto without the consent of the Company; <I>provided further</I>
that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or
substantially concurrently with, the first use of such term sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">It
is not subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering (and will promptly notify
the Company if any such proceeding against it is initiated during the Prospectus Delivery Period).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Conditions
of Underwriters&#8217; Obligations.</U> The obligation of each Underwriter to purchase the Underwritten Shares on the Closing Date or
the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company
of its covenants and other obligations hereunder and to the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Registration
Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding
for such purpose, pursuant to Rule&nbsp;401(g)(2)&nbsp;or pursuant to Section&nbsp;8A under the Securities Act shall be pending before
or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission
under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule&nbsp;433 under the Securities
Act) and in accordance with Section&nbsp;4(a)&nbsp;hereof; and all requests by the Commission for additional information shall have been
complied with to the reasonable satisfaction of the Representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Representations
and Warranties.</I> The representations and warranties of the Company contained herein shall be true and correct on the date hereof and
on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the Company and its officers made
in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing
Date, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Downgrade</I>. Subsequent to the earlier of (A)&nbsp;the Applicable Time and (B)&nbsp;the execution and delivery of this Agreement, (i)&nbsp;no
downgrading shall have occurred in the rating accorded any debt securities, convertible securities or preferred stock issued, or guaranteed
by, the Company or any of its subsidiaries by any &#8220;nationally recognized statistical rating organization,&#8221; as such term is
defined under Section&nbsp;3(a)(62) under the Exchange Act and (ii)&nbsp;no such organization shall have publicly announced that it has
under surveillance or review, or has changed its outlook with respect to, its rating of any such debt securities or preferred stock issued
or guaranteed by the Company or any of its subsidiaries (other than an announcement with positive implications of a possible upgrading).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(g)&nbsp;hereof shall have occurred or shall exist,
which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus
(excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable
or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the
case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Officer&#8217;s
Certificate.</I> The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may
be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer
of the Company who is satisfactory to the Representatives, on behalf of the Company and not in their individual capacity, (i)&nbsp;confirming
that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge
of such officers, the representations set forth in Sections 3(b)&nbsp;and 3(d)&nbsp;hereof are true and correct, (ii)&nbsp;confirming
that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied
in all material respects with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior
to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect set forth in paragraphs (a), (c)&nbsp;and
(d)&nbsp;above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Comfort
Letters.</I> On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, Deloitte&nbsp;&amp;
Touche LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery
thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements
and information of the type customarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters with respect to the
financial statements and certain financial information contained or incorporated by reference in each of the Registration Statement, the
Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date,
as the case may be, shall use a &#8220;cut-off&#8221; date no more than two business days prior to such Closing Date or such Additional
Closing Date, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Opinion
and 10b-5 Statement of Counsel for the Company.</I> Ropes&nbsp;&amp; Gray LLP, counsel for the Company, shall have furnished to the Representatives,
at the request of the Company, their written opinion and 10b-5 statement, dated the Closing Date or the Additional Closing Date, as the
case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Opinion
and 10b-5 Statement of Counsel for the Underwriters.</I> The Representatives shall have received on and as of the Closing Date or the
Additional Closing Date, as the case may be, an opinion and 10b-5 statement, addressed to the Underwriters, of Latham&nbsp;&amp; Watkins
LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall
have received such documents and information as they may reasonably request to enable them to pass upon such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Opinion
of Regulatory Counsel for the Company</I>. The Representatives shall have received on and as of the Closing Date or the Additional Closing
Date, as the case may be, an opinion, addressed to the Underwriters, from Waller Landsen Dortch&nbsp;&amp; Davis, LLP, counsel to the
Company for regulatory matters, in form and substance reasonably satisfactory to the Representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>No
Legal Impediment to Issuance and Sale.</I> No action shall have been taken and no statute, rule, regulation or order shall have been enacted,
adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional
Closing Date, as the case may be, prevent the issuance or sale of the Shares; and no injunction or order of any federal, state or foreign
court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance
or sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Good
Standing</I>. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be,
satisfactory evidence of the good standing of the Company and its significant subsidiaries in their respective jurisdictions of organization
and their good standing in such other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard
form of telecommunication from the appropriate governmental authorities of such jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Exchange
Listing</I>. The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case may be, shall have been approved
for listing on the Nasdaq Market, subject to official notice of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Lock-up
Agreements</I>. The &#8220;lock-up&#8221; agreements, each substantially in the form of Exhibit&nbsp;A hereto, between you and certain
shareholders, officers and directors of the Company relating to sales and certain other dispositions of shares of Stock or certain other
securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date or the Additional Closing
Date, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Additional
Documents.</I> On or prior to the Closing Date or the Additional Closing Date, as the case may be, the Company shall have furnished to
the Representatives such further certificates and documents as the Representatives may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All opinions, letters, certificates and evidence
mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form
and substance reasonably satisfactory to counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
and Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Indemnification
of the Underwriters.</I> The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors and officers
and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or
Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without
limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such
fees and expenses are incurred), joint or several, that arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state
therein a material fact required to be stated therein or necessary in order to make the statements therein, not misleading, or
(ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Pro</FONT>spectus (or any amendment
or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#8220;issuer information&#8221; filed
or required to be filed pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act, any road show as defined in
Rule&nbsp;433(h)&nbsp;under the Securities Act (a &#8220;road show&#8221;) or any Pricing Disclosure Package, or caused by any
omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities
arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and
in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the
Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any
Underwriter consists of the information described as such in paragraph (b)&nbsp;below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Indemnification
of the Company.</I> Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its
officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15
of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above,
but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission
or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished
to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus
(or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any road show or any Pricing
Disclosure Package, it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following
information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the third paragraph
under the caption &#8220;Underwriting&#8221; and the information contained in the eighteenth paragraph under the caption &#8220;Underwriting.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Notice
and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall
be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of
this Section&nbsp;7, such person (the &#8220;Indemnified Person&#8221;) shall promptly notify the person against whom such
indemnification may be sought (the &#8220;Indemnifying Person&#8221;) in writing; <U>provided</U> that the failure to notify the
Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs of this Section&nbsp;7
except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such
failure; and <U>provided</U>, <U>further</U>, that the failure to notify the Indemnifying Person shall not relieve it from any
liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any
such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person
thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the
consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any others
entitled to indemnification pursuant to this Section&nbsp;that the Indemnifying Person may designate in such proceeding and shall
pay the reasonable and documented fees and expenses in such proceeding and shall pay the reasonable and documented fees and expenses
of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to
retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless
(i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying
Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the
Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in
addition to those available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any
impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same
counsel would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the
Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the
fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such
fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter, its affiliates,
directors and officers and any control persons of such Underwriter shall be designated in writing by the Representatives and any
such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the
Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each
Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if
at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for reasonable
and documented fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any
settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days
after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the
Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the
written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect </FONT>of which
any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified
Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance
reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and
(y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any
Indemnified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Contribution.</I>
If the indemnification provided for in paragraphs (a)&nbsp;or (b)&nbsp;above is unavailable to an Indemnified Person or insufficient in
respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu
of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result
of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received
by the Company, on the one hand, and the Underwriters on the other, from the offering of the Shares or (ii)&nbsp;if the allocation provided
by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i)&nbsp;but also the relative fault of the Company, on the one hand, and the Underwriters, on the other, in connection
with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to
be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Shares
and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in
the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The relative fault of the Company, on the
one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company
or by the Underwriters and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent
such statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Limitation
on Liability.</I> The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to paragraph
(d)&nbsp;above were determined by <U>pro rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or
by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (d)&nbsp;above.
The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph
(d)&nbsp;above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred
by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and (e),
in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts
and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount of any damages that such Underwriter
has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty
of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#8217; obligations to contribute pursuant to
paragraphs (d)&nbsp;and (e)&nbsp;are several in proportion to their respective purchase obligations hereunder and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Non-Exclusive
Remedies.</I> The remedies provided for in this Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which may
otherwise be available to any Indemnified Person at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Effectiveness
of Agreement</U>. This Agreement shall become effective as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination</U>.
This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after the execution
and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional
Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange
or The Nasdaq Stock </FONT>Market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended
on any exchange or in any over-the-counter market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been
declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities
or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of
the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or
delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner
contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Defaulting
Underwriter</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If,
on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the Shares
that it has agreed to purchase hereunder on such date, the non-defaulting Underwriters may in their discretion arrange for the purchase
of such Shares by other persons satisfactory to the Company on the terms contained in this Agreement. If, within 36 hours after any such
default by any Underwriter, the non-defaulting Underwriters do not arrange for the purchase of such Shares, then the Company shall be
entitled to a further period of 36 hours within which to procure other persons satisfactory to the non-defaulting Underwriters to purchase
such Shares on such terms. If other persons become obligated or agree to purchase the Shares of a defaulting Underwriter, either the non&#45;defaulting
Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full business
days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in
the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any
amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the
term &#8220;Underwriter&#8221; includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed
in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Shares that a defaulting Underwriter agreed but failed to purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If,
after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting
Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing
Date or the Additional Closing Date, as the case may be, does not exceed one-eleventh of the aggregate number of Shares to be purchased
on such date, then the Company shall have the right to require each non-defaulting Underwriter to purchase the number of Shares that such
Underwriter agreed to purchase hereunder on such date plus such Underwriter&#8217;s pro rata share (based on the number of Shares that
such Underwriter agreed to purchase on such date) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements
have not been made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If,
after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting
Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing
Date or the Additional Closing Date, as the case may be, exceeds one-eleventh of the aggregate amount of Shares to be purchased on such
date, or if the Company shall not exercise the right described in paragraph (b)&nbsp;above, then this Agreement or, with respect to any
Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall
terminate without liability on the part of the non-defaulting Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10
shall be without liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses
as set forth in Section&nbsp;11 hereof (other than with respect to the defaulting underwriter(s)) and except that the provisions of Section&nbsp;7
hereof shall not terminate and shall remain in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Nothing
contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any non-defaulting Underwriter
for damages caused by its default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Payment
of Expenses</U><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Whether
or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or
cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation,
(i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes payable in
that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration
Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the Prospectus
(including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the reasonable and documented
fees and expenses of the Company&#8217;s counsel and independent accountants; (iv)&nbsp;the fees and ex</FONT>penses incurred in
connection with the registration or qualification and determination of eligibility for investment of the Shares under the laws of
such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum
(including the related reasonable and documented fees and expenses of counsel for the Underwriters not to exceed
$10,000);&nbsp;(v)&nbsp;the cost of preparing stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any
registrar; (vii)&nbsp;all expenses and application fees incurred in connection with any filing with, and clearance of the offering
by, FINRA (including the related reasonable and documented fees and expenses of counsel for the Underwriters not to exceed $15,000;
(viii)&nbsp;all expenses incurred by the Company in connection with any &#8220;road show&#8221; presentation to potential investors;
and (ix)&nbsp;all expenses and application fees related to the listing of the Shares on the Nasdaq Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
(i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii)&nbsp;the Company for any reason fails to tender the Shares for
delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Shares for any reason permitted under this Agreement,
the Company agrees to reimburse the Underwriters for all out-of-pocket accountable costs and expenses (including the fees and expenses
of their counsel) actually incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby; <I>provided</I>,
however, that no additional amounts beyond what has been reimbursed pursuant to the foregoing will be owed to the Underwriters other than
under Section&nbsp;7 hereof. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees
or expenses incurred by any Underwriter that defaults on its obligations to purchase the Shares pursuant to Section&nbsp;10 of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Persons
Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred
to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable
right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter
shall be deemed to be a successor merely by reason of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the Underwriters contained
in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant
hereto shall survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination
of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers, controlling
persons or affiliates referred to in Section&nbsp;7 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term &#8220;affiliate&#8221;
has the meaning set forth in Rule&nbsp;405 under the Securities Act; (b)&nbsp;the term &#8220;business day&#8221; means any day other
than a day on which banks are permitted or required to be closed in New York City; and (c)&nbsp;the term &#8220;subsidiary&#8221; has
the meaning set forth in Rule&nbsp;405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compliance
with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October&nbsp;26,
2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the
Company, which information may include the name and address of their respective clients, as well as other information that will allow
the Underwriters to properly identify their respective clients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Notices. </I>All
notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted
and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives: c/o BofA
Securities,&nbsp;Inc., One Bryant Park, New York, New York 10036, Attention: Syndicate Department (email:
dg.ecm_execution_services@bofa.com), with a copy to ECM legal, (email: dg.ecm_legal@bofa.com), c/o J.P. Morgan Securities LLC, 383
Madison Avenue, New York, New York 10179 (fax: (212) 622-8358), c/o Barclays Capital Inc., 745 Seventh Avenue, New York, New York
10019, Attention: Syndicate Registration (Fax: (646) 834-8133), with a copy, in the case of any notice pursuant to
Section&nbsp;7(c), to the Director of Litigation, Office of the General Counsel, Barclays Capital Inc., 745 Seventh Avenue, New
York, New York 10019, c/o Jefferies LLC, 520 Madison Avenue, New York, NY 10022; Attention Equity Syndicate Desk. Notices to the
Company shall be </FONT>given to it at Surgery Partners,&nbsp;Inc., 310 Seven Springs Way, Suite&nbsp;500, Brentwood, Tennessee,
37027, Attention: General Counsel, with a copy to: Ropes&nbsp;&amp; Gray LLP, Three Embarcadero Center, San Francisco, California
94111 Attention: L. Thomas Holden,&nbsp;Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Governing
Law.</I> This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed
in accordance with the laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Submission
to Jurisdiction</I>. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts in the Borough
of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby. The Company waives any objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such
courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding
upon the Company and may be enforced in any court to the jurisdiction of which Company is subject by a suit upon such judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Waiver
of Jury Trial.</I> Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of or relating
to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Recognition
of the U.S. Special Resolution Regimes</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;In the event that any Underwriter
that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of
this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would
be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws
of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)&nbsp;In the event that any Underwriter
that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime,
Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent
than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the
United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">As used in this Section&nbsp;16(g):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#8220;BHC Act Affiliate&#8221; has the
meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8220;Covered Entity&#8221; means any
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: 0.5in">(i)&nbsp;a &#8220;covered entity&#8221;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: 0.5in">(ii)&nbsp;a &#8220;covered bank&#8221;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: 0.5in">(iii)&nbsp;a &#8220;covered FSI&#8221;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#8220;Default Right&#8221; has the meaning
assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#8220;U.S. Special Resolution Regime&#8221;
means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank
Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Counterparts. </I>This
Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each
of which shall be an original and all of which together shall constitute one and the same instrument. The words
 &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; &#8220;delivery&#8221; and words of like import in or
relating to this Agreement or any document to be signed in connection with this Agreement shall be deemed to include electronic
signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or
enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the
case may be, and the </FONT>parties hereto consent to conduct the transactions contemplated hereunder by electronic means.
Electronic signatures complying with the New York Electronic Signatures and Records Act (N.Y. State Tech. &sect;&sect; 301-309), as
amended from time to time, or other applicable law will be deemed original signatures for purposes of this Agreement. Transmission
by telecopy, electronic mail or other transmission method of an executed counterpart of this Agreement will constitute due and
sufficient delivery of such counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Amendments
or Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall
in any event be effective unless the same shall be in writing and signed by the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><I>Headings.</I>
The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation
of, this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the foregoing is in accordance with your understanding,
please indicate your acceptance of this Agreement by signing in the space provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">SURGERY PARTNERS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ David T. Doherty</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-size: 10pt">David T. Doherty</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Executive Vice President and Chief Financial Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Underwriting
Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted: As of the date first written above&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BOFA SECURITIES,&nbsp;INC.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. MORGAN SECURITIES LLC&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BARCLAYS CAPITAL INC.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">JEFFERIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For themselves and on behalf of the<BR>
several Underwriters listed<BR>
in Schedule 1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">BOFA SECURITIES,&nbsp;INC.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">/s/ Sumit Mukherjee</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">J.P. MORGAN SECURITIES LLC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Alejandra Fernandez</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">BARCLAYS CAPITAL INC.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Victoria Hale</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">JEFFERIES LLC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Mike Bauer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Schedule 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Underwriter</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Number of Shares</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: left; padding-bottom: 1pt">BofA Securities,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">4,391,047</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">J.P. Morgan Securities LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,391,047</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Barclays Capital Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,391,047</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Jefferies LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,391,047</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">RBC&nbsp;Capital Markets, LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,968,400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">KKR Capital Markets LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">984,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Macquarie Capital (USA) Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">984,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Mizuho Securities USA LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">984,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">SVB Securities LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">984,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: right; padding-bottom: 1pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23,469,388</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Schedule 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Significant Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Attached.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Schedule 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Joint Ventures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Attached.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Annex A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Pricing
Disclosure Package</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Pricing
Information Provided Orally by Underwriters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwritten
Shares: </FONT>23,469,388</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
Shares: </FONT>3,520,408</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Public Offering Price Per Share: $24.50</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Concurrent Private Placement: Concurrently with the sale
of the Shares, the Company will sell 9,183,673 shares of common stock of the Company in a private placement to BCPE, at a price per share
of $24.50.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">Annex B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Reserved]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit&nbsp;A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM&nbsp;OF LOCK-UP AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Attached.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2230583d4_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;5.1</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="text-align: left; font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 13%">&nbsp;<IMG SRC="tm2230583d4_ex5-1img002.jpg" ALT=""></TD>
  <TD STYLE="width: 87%; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                   <P STYLE="margin-top: 0; margin-bottom: 0">ROPES&nbsp;&amp;
GRAY LLP&nbsp;<BR> 1211 AVENUE OF THE AMERICAS&nbsp;<BR> NEW YORK, NY 10036-8704&nbsp;<BR> WWW.ROPESGRAY.COM</P></TD>
</TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">November&nbsp;21, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Surgery Partners,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">310 Seven Springs Way, Suite&nbsp;500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brentwood, Tennessee 37027</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Re:</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Registration
Statement on Form&nbsp;S-3ASR (File No.&nbsp;333-252399)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have acted as counsel to Surgery Partners,&nbsp;Inc.,
a Delaware corporation (the &#8220;<U>Company</U>&#8221;), in connection with issuance and sale of up to 26,989,796 shares of the common
stock, $0.01 par value (the &#8220;<U>Shares</U>&#8221;), of the Company pursuant to the above-referenced registration statement (the
 &#8220;<U>Registration Statement</U>&#8221;), filed by the Company with the Securities and Exchange Commission (the &#8220;<U>Commission</U>&#8221;)
under the Securities Act of 1933, as amended (the &#8220;<U>Securities Act</U>&#8221;). The Shares are being sold pursuant to an underwriting
agreement, dated the date hereof (the &#8220;<U>Underwriting Agreement</U>&#8221;), by and among the Company and BofA Securities,&nbsp;Inc.,
J.P. Morgan Securities LLC, Barclays Capital Inc. and Jefferies LLC, as representatives of the several underwriters listed on Schedule
1 thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with this opinion letter, we have
examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed
appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent
verification, upon certificates of officers of the Company, public officials and other appropriate persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The opinions expressed below are limited to the
Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based upon and subject to the foregoing, we are
of the opinion that the Shares have been duly authorized and, when issued and delivered pursuant to the Underwriting Agreement against
payment of the consideration set forth therein, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We hereby consent to your filing this opinion as
an exhibit to the Registration Statement and to the use of our name therein and in the related prospectus under the caption &#8220;Legal
Matters.&#8221; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under
Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Ropes&nbsp;&amp; Gray LLP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Ropes&nbsp;&amp; Gray LLP</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>tm2230583d4_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="text-align: left; margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="text-align: left; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: left; margin: 0pt"><I>EXECUTION VERSION</I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>STOCK PURCHASE AGREEMENT</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>This
Stock Purchase Agreement</B></FONT> (<B><I>&#8220;Agreement&#8221;</I></B>) is entered into as of November&nbsp;21, 2022 (the <B><I>&#8220;Execution
Date&#8221;</I></B>), by and between <FONT STYLE="font-variant: small-caps"><B>Surgery Partners,&nbsp;Inc.</B></FONT>, a Delaware corporation
(<B><I>&#8220;Surgery&#8221;</I></B>), and Bain Capital Fund XI, L.P., a Cayman Islands limited partnership (<B><I>&#8220;Bain Capital&#8221;</I></B>).
Surgery and Bain Capital may individually be referred to as a <B><I>&#8220;Party&#8221;</I></B> and together as the <B><I>&#8220;Parties&#8221;</I></B>.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Agreement</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For good and valuable consideration,
the Parties agree as follows:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="text-transform: capitalize"><B>Section</B></FONT><B><FONT STYLE="font-variant: small-caps">&nbsp;1.&#9;Sale
and Purchase of Stock</FONT></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Purchase
of Stock. </FONT></B><FONT STYLE="font-size: 10pt">Subject to the terms and conditions of this Agreement, at the Closing, Surgery will
issue and sell to Bain Capital, and Bain Capital will purchase from Surgery, 9,183,673 shares of Common Stock, par value $0.01 per share
(the <B><I>&#8220;Shares&#8221;</I></B>), at a price equal to $24.50 per share, for an aggregate purchase price of $224,999,988.50 (the
 &#8220;<B><I>Purchase Price</I></B>&#8221;).</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment;
Delivery of Shares.</FONT></B><FONT STYLE="font-size: 10pt"> At the Closing, Bain Capital will pay the Purchase Price by wire transfer
of immediately available funds in accordance with wire instructions provided by Surgery to Bain Capital at least one (1)&nbsp;Business
Day prior to the Closing, and Surgery will deliver the Shares in book-entry form to Bain Capital.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Closing.</FONT></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(a)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">The
closing of the transactions contemplated by this <U>Section&nbsp;1</U> (the <B><I>&#8220;Closing&#8221;</I></B>) will be held through
the electronic exchange of documents and signatures, as promptly as practicable, and in no event later than the first Business Day after
the conditions to closing set forth in <U>Section&nbsp;5</U> are satisfied or waived (other than those conditions that by their nature
are to be satisfied or waived at the Closing but subject to the satisfaction or waiver of those conditions) or at such other place, time
and/or date as may be jointly designated by Bain Capital and Surgery (the <B><I>&#8220;Closing Date&#8221;</I></B>); provided, that in
no event will the Closing occur prior to December&nbsp;23, 2022 without the prior written consent of Bain Capital.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(b)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">Closing
Deliverables.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-size: 10pt"><B>(i)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">At
the Closing, Surgery shall deliver to Bain Capital:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"><FONT STYLE="font-size: 10pt"><B>(1)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">a
certificate of the secretary of Surgery dated as of the Closing Date certifying that attached thereto is a true and complete copy of
all resolutions adopted by Surgery&#8217;s Board of Directors (the &#8220;<B><I>Board</I></B>&#8221;) authorizing the execution, delivery
and performance of this Agreement and the transactions contemplated respectively herein and that all such resolutions are in full force
and effect and are all the resolutions adopted in connection with such transactions as of the Closing Date;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"><FONT STYLE="font-size: 10pt"><B>(2)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">a
written statement of Surgery&#8217;s transfer agent, indicating issuance of the Shares in the name of Bain Capital or its designee.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-size: 10pt"><B>(ii)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">At
the Closing, Bain Capital will deliver to Surgery:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"><FONT STYLE="font-size: 10pt"><B>(1)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">a
certificate in form and substance reasonably satisfactory to Surgery and duly executed on behalf of Bain Capital by an authorized officer
of Bain Capital, certifying that the conditions to Closing set forth in <U>Section&nbsp;5.1</U> of this Agreement have been fulfilled;
and</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"><FONT STYLE="font-size: 10pt"><B>(2)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">the
Purchase Price for the Shares by wire transfer of immediately available federal funds to an account designated in writing by Surgery
at least one (1)&nbsp;Business Day in advance of the Closing.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-transform: capitalize"><B>Section</B></FONT><B><FONT STYLE="font-variant: small-caps">&nbsp;2.&#9;Representations
and Warranties of Surgery</FONT></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Surgery hereby represents
and warrants to Bain Capital as of the date hereof and as of the Closing Date as follows:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Private
Placement.</FONT></B><FONT STYLE="font-size: 10pt"> Neither Surgery nor any person acting on its behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under any </FONT>circumstances that would
require registration of the Shares under the Securities Act of 1933, as amended (the &#8220;<B>Securities Act</B>&#8221;). Subject
to the accuracy of the representations made by Bain Capital in <U>Section&nbsp;3</U>, the Shares will be issued and sold to Bain
Capital in compliance with applicable exemptions from the registration and prospectus delivery requirements of the Securities Act
and the registration and qualification requirements of all applicable securities laws of the states of the United States. Surgery
has not engaged any brokers, finders or agents, or incurred, nor will it incur, directly or indirectly, any liability for brokerage
or finder&#8217;s fees or agents&#8217; commissions or any similar charges in connection with this Agreement and the transactions
contemplated hereby.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Organization
and Qualification.</FONT></B><FONT STYLE="font-size: 10pt"> Surgery is duly incorporated, validly existing and in good standing under
the laws of the State of Delaware with full corporate power and authority to conduct its business as currently conducted.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Authorization;
Enforcement.</FONT></B><FONT STYLE="font-size: 10pt"> Surgery has all requisite corporate power and authority to enter into and to perform
its obligations under this Agreement, to consummate the transactions contemplated hereby and to issue the Shares in accordance with the
terms hereof. The execution, delivery and performance of this Agreement by Surgery and the consummation by it of the transactions contemplated
hereby (including the issuance of the Shares) have been duly authorized by the Board and no further consent or authorization of Surgery,
the Board or Surgery&#8217;s stockholders is required in connection therewith. This Agreement has been duly executed by Surgery and constitutes
a legal, valid and binding obligation of Surgery enforceable against Surgery in accordance with its terms.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.4</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Issuance
of Shares.</FONT></B><FONT STYLE="font-size: 10pt"> The Shares are duly authorized and, upon issuance in accordance with the terms of
this Agreement, will be validly issued, fully paid and non-assessable and will not be subject to preemptive rights or other similar rights
of stockholders of Surgery.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-transform: capitalize"><B>Section</B></FONT><B><FONT STYLE="font-variant: small-caps">&nbsp;3.&#9;Representations
and Warranties of Bain Capital.</FONT></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Bain Capital hereby represents
and warrants to Surgery as of the Execution Date and as of the Closing Date as follows:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Authorization;
Enforcement. </FONT></B><FONT STYLE="font-size: 10pt"> Bain Capital has the requisite entity power and authority to enter into this Agreement
and to consummate the transactions contemplated hereby. Bain Capital has taken all necessary corporate or similar action to authorize
the execution, delivery and performance of this Agreement. Upon the execution and delivery of this Agreement, this Agreement will constitute
a valid and binding obligation of Bain Capital, enforceable against Bain Capital in accordance with its terms, except as (a)&nbsp;enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; and contracting
parties&#8217; rights generally, and (b)&nbsp;enforceability may be subject to general principles of equity.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Investment
Purpose.</FONT></B><FONT STYLE="font-size: 10pt"> Bain Capital is purchasing the Shares for its own account and not with a present view
toward the public distribution thereof and has no arrangement or understanding with any other persons regarding the distribution of such
Shares, except as would not result in a violation of the Securities Act.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Accredited
Investor; Access to Information.</FONT></B><FONT STYLE="font-size: 10pt"> Bain Capital is an &#8220;accredited investor&#8221; as defined
in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions
with respect to, investments in shares presenting an investment decision like that involved in the purchase of the Shares.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.4</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Brokers
and Finders.</FONT></B><FONT STYLE="font-size: 10pt"> No person will have, as a result of the transactions contemplated by this Agreement,
any valid right, interest or claim against or upon Surgery for any commission, fee or other compensation pursuant to any agreement, arrangement
or understanding entered into by or on behalf of Bain Capital.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-transform: capitalize"><B>Section</B></FONT><B><FONT STYLE="font-variant: small-caps">&nbsp;4.&#9;Legends.</FONT></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Legends.
</FONT></B><FONT STYLE="font-size: 10pt">Bain Capital understands the Shares will bear a restrictive legend in substantially the following
form (and a stop-transfer order may be placed against transfer of the Shares):</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>THE SECURITIES REPRESENTED
BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &quot;ACT&quot;), OR UNDER ANY STATE SECURITIES
LAWS AND MAY&nbsp;NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE
SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION THEREUNDER<FONT STYLE="color: #333333">.</FONT></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-transform: capitalize"><B>Section</B></FONT><B><FONT STYLE="font-variant: small-caps">&nbsp;5.&#9;Conditions
to Closing</FONT></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Conditions
to Obligations of Surgery.</FONT></B><FONT STYLE="font-size: 10pt"> Surgery&#8217;s obligation to complete the purchase and sale of the
Shares and deliver the Shares to Bain Capital is subject to the fulfillment or waiver of the following conditions at or prior to the
Closing:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(a)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Receipt
of Funds</U>. Surgery will have received immediately available funds in the full amount of the Purchase Price for the Shares being purchased
hereunder.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(b)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Representations
and Warranties</U>. The representations and warranties made by Bain Capital in <U>Section&nbsp;3</U> will be true and correct in all
material respects as of the Closing Date, except to the extent such representations and warranties are made as of another date, in which
case such representations and warranties will be true and correct in all material respects as of such other date.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(c)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Closing
Deliverables</U>. All closing deliverables as required under <U>Section&nbsp;1.3(b)(ii)</U>&nbsp;shall have been delivered by Bain Capital
to Surgery.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Conditions
to Bain Capital&#8217;s Obligations at the Closing.</FONT></B><FONT STYLE="font-size: 10pt"> Bain Capital&#8217;s obligation to complete
the purchase and sale of the Shares is subject to the fulfillment or waiver of the following conditions at or before the Closing:</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(a)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Representations
and Warranties</U>. The representations and warranties made by Surgery in <U>Section&nbsp;2</U> will be true and correct as of the Closing
Date, except to the extent such representations and warranties are made as of another date, in which case such representations and warranties
will be true and correct as of such other date.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(b)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Closing
Deliverables</U>. All closing deliverables as required under <U>Section&nbsp;1.3(b)(i)</U>&nbsp;shall have been delivered by Surgery
to Bain Capital.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(c)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Public
Offering.</U> The concurrent underwritten public offering of at least $575 million of Common Stock of Surgery shall have been consummated
on or before the Closing.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(d)</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt"><U>Amendment
to Registration Rights Agreement</U>. The Registration Rights Agreement, by and among Surgery Partners,&nbsp;Inc. and certain stockholders
party thereto, dated as of August&nbsp;31, 2017, shall be amended to include the Shares as &#8220;Registrable Shares&#8221; (as defined
therein) at or before the Closing.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-transform: capitalize"><B>Section</B></FONT><B><FONT STYLE="font-variant: small-caps">&nbsp;6.&#9;Governing
Law; Miscellaneous.</FONT></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Business
Day</FONT></B><FONT STYLE="font-size: 10pt">. For the purposes of this Agreement, a <I>&#8220;</I>Business Day<I>&#8221;</I> means any
day, other than any Saturday, Sunday, or any day that banks are authorized or required to be closed in Brentwood, Tennessee or Boston,
Massachusetts.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Governing
Law; Jurisdiction.</FONT></B><FONT STYLE="font-size: 10pt"> This Agreement will be governed by and interpreted in accordance with the
laws of the State of Delaware without regard to the principles of conflict of laws.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Counterparts;
Signatures by Facsimile.</FONT></B><FONT STYLE="font-size: 10pt"> This Agreement may be executed in two counterparts, both of which are
considered one and the same agreement and will become effective when the counterparts have been signed by each Party and delivered to
the other Party hereto. This Agreement, once executed by a Party, may be delivered to the other Party hereto by electronic PDF of a copy
of this Agreement bearing the signature of the Party so delivering this Agreement.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.4</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Headings.
</FONT></B><FONT STYLE="font-size: 10pt">The headings of this Agreement are for convenience of reference only, are not part of this Agreement
and do not affect its interpretation.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.5</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Severability.
</FONT></B><FONT STYLE="font-size: 10pt">If any provision of this Agreement should be held invalid, illegal or unenforceable in any jurisdiction,
the parties will negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent
of the parties and all other provisions hereof will remain in full force and effect in such jurisdiction and will be liberally construed
in order to carry out the intentions of the parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability
will not affect the validity, legality or enforceability of such provision in any other jurisdiction.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.6</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Further
Assurances; Survival.</FONT></B><FONT STYLE="font-size: 10pt"> Each Party will do and perform, or cause to be done and performed, all
such further acts and things, and will execute and deliver all other agreements, certificates, instruments and documents, as the other
Party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby. The representations and warranties contained in this Agreement shall survive the Closing of the transactions
contemplated by this Agreement.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.7</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Construction.
</FONT></B><FONT STYLE="font-size: 10pt">The Parties acknowledge and agree that (a)&nbsp;each Party and its counsel reviewed and negotiated
the terms and provisions of this Agreement and have contributed to its revision; (b)&nbsp;the rule&nbsp;of construction to the effect
that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c)&nbsp;the
terms and provisions of this Agreement shall be construed fairly as to each Party and not in a favor of or against either Party, regardless
of which Party was generally responsible for the preparation of this Agreement.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.8</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Amendment
and Waiver. </FONT></B><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any provision of this Agreement
may be amended or modified only by a written instrument signed by each Party. No waiver hereunder shall be valid or binding unless set
forth in writing and duly executed by the Party against whom enforcement of the waiver is sought. Any such waiver shall constitute a
waiver only with respect to the specific matter described in such writing and shall in no way impair the rights of the Party granting
such waiver in any other respect or at any other time. Neither the waiver by any Party of a breach of or a default under any provision
of this Agreement, nor the failure by any Party, on one or more occasions, to enforce any provision of this Agreement or to exercise
any right or privilege hereunder, shall be construed as a waiver of any other breach or default of a similar nature, or as a waiver of
any such provision, right or privilege hereunder.</FONT></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.9</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Assignment</U>.
</FONT></B><FONT STYLE="font-size: 10pt">Neither this Agreement nor any rights, interests or obligations hereunder shall be assigned
by any Party (whether by operation of law or otherwise) without the prior written consent of the other Party, and any purported assignment
without such consent shall be null and void <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>ab initio</I></FONT>. Notwithstanding
the foregoing, Bain Capital shall have the right to assign all or a portion of its rights pursuant to this Agreement, or any interest
herein, and may delegate any duty or obligation hereunder, without the consent of Surgery, to any affiliate of Bain Capital; <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>provided
</I></FONT>that, no such assignment or delegation shall relieve Bain Capital of any of its obligations hereunder.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof, </B></FONT>Bain Capital and Surgery have caused this Agreement to be duly executed as of the date first above written.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; font-variant: small-caps">Surgery Partners Inc.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ David T. Doherty</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 3%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%">Name:</TD>
    <TD STYLE="font-size: 10pt; width: 42%">David T. Doherty</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">Executive Vice President and Chief Financial Officer</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>EXECUTION VERSION</I></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; font-variant: small-caps">Bain Capital Fund XI, L.P. &nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2">Bain Capital Partners XI, L.P., its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2">Bain Capital Investors, LLC, its General Partner &nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Andrew Kaplan</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 42%">Andrew Kaplan</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Managing Director, Private Equity</TD></TR>
  </TABLE>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page to Stock Purchase Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sgry-20221121.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaePSbOdzZR+KYkxtmB7bTlKbyAuxfsRRy65Rmn2gRkP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:sgry="http://surgerypartners.com/20221121" elementFormDefault="qualified" targetNamespace="http://surgerypartners.com/20221121">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://surgerypartners.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="sgry-20221121_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="sgry-20221121_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>sgry-20221121_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>sgry-20221121_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://surgerypartners.com/role/Cover" xlink:href="sgry-20221121.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://surgerypartners.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2230583d4_ex5-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2230583d4_ex5-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K %4# 2(  A$! Q$!_\0
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MGD9P_/Z#\J77 (_C)IK)\I?3DW$<;OW_ 'H4583G*_E>QZ-11161N<;\5O\
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M\0O^)-XG\,^*64FVM9FM[DC^!7Z']6_2NUDTK3;O48=5>W22Z2,)'/D\)G<
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139786757162048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 21,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Surgery Partners, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3620923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">310 Seven Springs Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brentwood<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">234-5900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGRY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>tm2230583d4_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sgry-20221121.xsd" xlink:type="simple"/>
    <context id="From2022-11-21to2022-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-11-21to2022-11-21">0001638833</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-11-21to2022-11-21">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-11-21to2022-11-21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-11-21to2022-11-21">2022-11-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-11-21to2022-11-21">Surgery Partners, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-11-21to2022-11-21">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-11-21to2022-11-21">001-37576</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-11-21to2022-11-21">47-3620923</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-11-21to2022-11-21">310 Seven Springs Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-11-21to2022-11-21">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-11-21to2022-11-21">Brentwood</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-11-21to2022-11-21">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-11-21to2022-11-21">37027</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-11-21to2022-11-21">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-11-21to2022-11-21">234-5900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-11-21to2022-11-21">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-11-21to2022-11-21">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-11-21to2022-11-21">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-11-21to2022-11-21">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-11-21to2022-11-21">Common     Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-11-21to2022-11-21">SGRY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-11-21to2022-11-21">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-11-21to2022-11-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M]X!V5>K?G)E@!   )1$  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R-
MF&]SHS80QM_W4VAHI]/.) &$_R6U/>,XR35S=SE?<)MI.WTA@VQK HB3A!U_
M^ZZP [D4+\Z+&&'VX:?5\JSP<"O5LUYS;LA+FF1ZY*R-R:]<5T=KGC)](7.>
MP3=+J5)F8*A6KLX59W$9E"8N];R>FS*1.>-A>6ZFQD-9F$1D?*:(+M*4J=TU
M3^1VY/C.ZXE'L5H;>\(=#W.VXB$W?^0S!2.W4HE%RC,M9$847XZ<B7]U3;LV
MH+SB3\&W^LTQL5-92/EL!_?QR/$L$4]X9*P$@X\-G_(DL4K \>T@ZE3WM(%O
MCU_5[\K)PV063/.I3)Y$;-8C9^"0F"]9D9A'N?V='R94 D8RT>5_LMU?V^DX
M)"JTD>DA& A2D>T_V<LA$:<$T$, +;GW-RHI;YAAXZ&26Z+LU:!F#\JIEM$
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MH*OV[^3[@9%Y^1Z\D ;>JLO#-6?P.-@+X/NEE.9U8%^MJU]&QO\!4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ]X!V59E<G",0!@  G"<  !,
M             ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #W@'95ZM^<F6 $   E$0  &               @($,"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ]X!V59^@&_"Q @  X@P   T
M             ( !H@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #W@'95
MEXJ[',     3 @  "P              @ %^#P  7W)E;',O+G)E;'-02P$"
M% ,4    " #W@'95JL0B%C,!   B @  #P              @ %G$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ ]X!V520>FZ*M    ^ $  !H
M         ( !QQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ ]X!V5660>9(9 0  SP,  !,              ( !K!(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ]A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2230583d4_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://surgerypartners.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2230583d4_8k.htm">tm2230583d4_8k.htm</File>
    <File>sgry-20221121.xsd</File>
    <File>sgry-20221121_lab.xml</File>
    <File>sgry-20221121_pre.xml</File>
    <File>tm2230583d4_ex1-1.htm</File>
    <File>tm2230583d4_ex10-1.htm</File>
    <File>tm2230583d4_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2230583d4_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2230583d4_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgry-20221121_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgry-20221121_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sgry-20221121.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "sgry",
   "nsuri": "http://surgerypartners.com/20221121",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2230583d4_8k.htm",
      "contextRef": "From2022-11-21to2022-11-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://surgerypartners.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2230583d4_8k.htm",
      "contextRef": "From2022-11-21to2022-11-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-22-121217-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-121217-xbrl.zip
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M@Z\%3Y\+:*KP@)!D"N\3U7.RN</!<37 ]:"@**F7X<98#L5ZDH J)62N,MI
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M\<M&G,T3GNYZP3"4KMD K.IX:+*@"+%[ R&IY?XYN>>89HELS'I!,:7.3T,
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MM_]<I;DO _NA&KW'% H=9PMG2!X&[BQAAB:%6P,FB(AMZK7=<^?)Y.M+08.
ML\<3*!IMBN KY?R#D$LQHD1+09,B'0C-$GB+0".!."=9(Q<M#%\DSRPIE2]
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M8P!)M,O3=G0F&5?_!:X*GDYG@A/V_PT1G(M0O#([?,^UM\AS[1/4UPPU]!X
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M/P^=>I_=7FF_SL]W[@?UKS^8\FNW<?SG9:Y7E?+VZ='CIT^")?\!4$L#!!0
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M_VK2?(;'(GKP0(*D/[Q^\_<P:OF@+M;PD4?K6I_]8%K4=;'Z/GJ&OYL6)1P
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M)8?L:4(P,UY 6" 0;O6ZR-GH2&:SHIPGZ%^;H!H8)17K3+0(^P45)P&KSEF
M%>"D 9SM)8@^4.87A9L8'M$J#!F&.PLOE+V#A\-IS189!L<TK?&E"8EK=.RF
MM^S8D=]% $/)@;>-4<R$I#GEI%" HYO23)?9#/80@>!PXMLH*LK1@65)7@]\
MC3YH/J(V%>69L!#'Z$N68!SN[09N#P,@$/PN+RZ6Z?S4&L!#TT!IP"-QOJLW
M:PJ"^Y1%<WI&HCK(G, %-D^Z#SY,9C=_1D^2S8H2.HLB.#I.^A!D M5;5DK^
M9<'F6K9:I7/<.G2Y':1BT= !%WL+Q"%Z%T[RM'T%E\\.5*0@("31W@8S>SO-
MPY[A%,TXB?<V@5,I$(+_3%;K%]$_DOICEF,9Q0E^_NCA]P\?1L>'OPAPJQL1
MQVO3BH<_!A6/ 7$R)N A)*<+E*+RC9)S@GKC2 VJ[<J?0[D<DU)KZ:M%MH K
M:24Z9YU)*SG,06>)5)/K4N*UHWO)J!8T?R3(@XJZ9T$#7>\\8:<^+)"'E#[-
MK[V30[9IVQKJ0:1+P .,8,'+V# -+5SH"Y)("O6O:NIU^Q#W&?7[X,:L;>%P
M&PZ*%+Q[H=LK+X_TW3SJ\4@7-EOH2>FS8 C/UL6VM\9U["'[/4.\^Y)ROVS-
MXZ\K,?/X/C%SX\KXI'4Y!P(L17 QQR/R+>0K W>O'PT6JLWD- '-4WL3O%_?
MN=&9$+*HSLIE97ICGH%%N&-6T94GQ>A_TM>J_^OD$[Q08W<]N$?6@DLOHV6,
M\P;,!7(@0U/@$(O->)'"284K*K8CN[F+9 ;&(X5EX3NH'EZG%&LJX"D?R@96
MWI4DB2!]_>&509\O&9#:W1!^*8GM"PP_X"Z6S:QF)31+RQJ4X P6K.H83H0T
M<@? VT4%&DV\O44N;C3:VKCTLA3M4036#4X11H\;B-C9>5J!E"+PQ PF6H E
M!CJG95X<H:ES J;.4.*?@]_6] A\R:N>G/&(C\[7[%_.;SMQN,M)ZYPN,6O8
M. E3*;Z$$B.,<&.=_0B'%@\0>VM)N=*TU7BT3/-3!CS7&,C$+ *)L+3$0-NF
M%??JQ;5:3U>N4P!?DR*EB:]RZ$H>3$R@PYNY<B2&68I4T5<<N#0AXE'!",^3
M? :>=)3,S[,*SCH:^O#K>0._)<G-MC\6AA)$;1%FL>AO&UG,-2QBD1^.1_ZR
M8+(F3S/ZL\,HAQN2!\\(@N,5#TMGM.6E$@S$7R_3TV09HZB.T:."5]22"F/=
MPKZ!8FU19JZ26B(1]( _FC*KYAFM;1@18/D(*U\U2ZX.(Z%47.2Z?D%1&"D
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M <#ZX<V/ T5 A\CA")(IHI "(JO/4Z<XJZ9"U:1*N:E2%0 #6&<LJ)VF:<Y
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M-.,T8>?@)85R8F=5:^LCWGE:>_?&751.?+!+D%X)]:!A!_OWCR7FD/BO5?%
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M^?LO?! L (9NV=-G</TG1Y:UH>>^,?T#,I5+(S/FI?!=K!$26W D(,L/)"5
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MQ&D7;R5]NUU$C F)V';<JVG<C(PI*GNTK0 J.WD"#\-^9>O&=Y#DM*?DZEU
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MHZC0QI4CD49MCXI^Z8<5-F+Z4P+47PIFY_:;$?RVACN-F4L\F4</IP^>VO[
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M0*5$Z<&[ >') TJ'89_G"'5B,AF2T/KC*!?,"%4H!HK.D!U)B,,@PV2/2L?
M'X)L,EF!@HVO#[V 5(@420:9TT;](D![N%W7&!S&AW#T:1%A.2QZNRP3-'
MS#KYZ%L5_[J\OJ:,/YN6L]YOYVSKHN]:E> 1/-U+)[BSI6&J_L46.%_:LZUR
MA!E9GTE0\['?(<_W&'+OA%_8!#>U^VE]K7.3<]N]_TJNE/^&+O-^V4S^U?*O
MG1R;Y1:'(SML80:8^:A5SRAL98OG6/PQ^%O]FS"G/W*7.>O,#VZ<OF[6GIY6
M;:MT4%I?.W,Z'H2-RFQUAF[&M K[A];FM?/KD[59+!2WK+UB<?N@M'O 7U)Q
M@G87RE2KSL #OD5:LOV=7?9.PH!G/WY]C2U;X3!CV8QZSLT3',+>SMZ6=5#:
MV3XHE$KF"B5H8@AKB7PU!IF?Z3TSC\(6HG',W7/X]JDGG'XF .BKBZO]"^=!
MJ8I.@D];@_6UI.C &N"6N9AS$;NT6\Q;(S;I)WRUR$Q[N7Q6#;FV#-D+[^*G
M)*7W%5=#\J  +5AD-8?!#01AF-1'?8A5Z*>B5,C3]*PFX&1N0NN'PS:AR0;
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MFO79K5[IH)@#R5MT5:6K?<-6B*E\@?F#I=)5OERS9^AV8\7T(UNP0?J*8"_
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M=HP/1 P<BPC'8Q@O%<XHC. DQR3@Y>$"<=XBEXQL4"B3!^/DBF>< 0G&A8Y
MRD"F"8 PC+OJ_B&_&P(;05LQFR3.Q'.;3P6,.--4I_ *M1(X=T.TZ1"5X\01
MS12M0"775Z@8X4ETD$.),7P%_9S%!\1)0H<73J#>+HM =0Q6<UCUHD&AO>)P
M(Z^J'@! #U 5)JBNV,-33P-,1#:Z?ZOTQTK6EJVRA-T@E@AZD=3V:(7K,DF
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MD/(?&@)+Z ZY0GP6NOFCFM6:/QWIUI2I,7F7INJ&&D:I-K6(J?#50'(2G1F
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M^Q&Z])DU+?7RDA[5R#ALGYR<MXZ..J>__/O5FU?T^^*\=6A_WW2FS''THB
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MV,B-@[.C/_;Q/Y]ZGT_V_Q]02P,$%     @ ]X!V5=FF(SXC!P  <!H  !4
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M66%(*XVS)5;<AN(KCAGO(SZJQ&W06VJ3)FRI#[K*.0#;%-C5O4+J!["\W['
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M2/1+TU]02P$"% ,4    " #W@'95!SL05CX#   *#   $0
M@ $     <V=R>2TR,#(R,3$R,2YX<V102P$"% ,4    " #W@'95Y'U0^?\*
M  !LAP  %0              @ %M P  <V=R>2TR,#(R,3$R,5]L86(N>&UL
M4$L! A0#%     @ ]X!V57WFG8!:!P  SU@  !4              ( !GPX
M '-G<GDM,C R,C$Q,C%?<')E+GAM;%!+ 0(4 Q0    ( /> =E4$-P<%%Q8
M !A]   2              "  2P6  !T;3(R,S U.#-D-%\X:RYH=&U02P$"
M% ,4    " #W@'95;K@;BJR1   #9@, %0              @ %S+   =&TR
M,C,P-3@S9#1?97@Q+3$N:'1M4$L! A0#%     @ ]X!V51V^?Z2#&P  =J4
M !8              ( !4KX  '1M,C(S,#4X,V0T7V5X,3 M,2YH=&U02P$"
M% ,4    " #W@'95V:8C/B,'  !P&@  %0              @ $)V@  =&TR
H,C,P-3@S9#1?97@U+3$N:'1M4$L%!@     '  < SP$  %_A      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
